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South Africa is among the countries facing rising numbers of Mycobacterium tuberculosis 
(Mtb) drug resistant strains. In 2000, DOTS-Plus strategy was introduced nationally to combat 
drug resistant tuberculosis (TB). This necessitated the introduction of drug susceptibility 
testing for second-line drugs (SLDs) in order to detect and treat cases in a timely and effective 
manner. However, this was only routinely implemented following the description of extensively 
drug resistant (XDR-TB, defined as MDR-TB plus resistance to a fluoroquinolone and a 
second-line injectable, in South Africa in 2006.  
 
The impact of implementing a standardized MDR-TB therapy policy in South Africa on 
individual treatment outcomes and acquisition of additional drug resistance has not been 
widely documented. Improved knowledge of factors that lead to acquisition of second-line drug 
resistance will help better predict who is most at risk of drug resistance and contribute to the 
development of new tools and strategies to combat MDR-TB. To fill this gap, we sought to 
determine the prevalence of SLD resistance among MDR-TB patients in the DOTS-Plus cohort 
and its impact on treatment outcomes for these patients in two provinces in South Africa; 
Eastern Cape (EC) and North West (NW) province. 
 
The results show that treatment success was strongly influenced by the setting where the 
patients were treated. Default and death accounted for 58.1% (193/333) of all unfavourable 
outcomes in provinces. The EC province had the lowest (13.4%, 51/381) cure rate and the 
highest default rate of 38.3%; compared to a default rate of 6.39% in NW. 
 
This study also describes the resistance patterns against second line drugs among newly 
diagnosed MDR-TB patients in the NW and EC province using Genotype MTBDRsl assay 
(version 1) and targeted sequencing of genes known to confer resistance, and how these 
patients acquired resistance during treatment. These finding have important implications for 
infection control, because undiagnosed highly resistant strains could have been transmitted 
to contacts during treatment. The concordance between Genotype MTBDRsl and sequencing 
was 82% for all gyrA gene and 67% for the rrs gene. Resistance to all drugs (including 
ethambutol) tested at baseline was 15.8% (47/298) and resistance to both ofloxacin and 
kanamycin was 1.3% (4/298). Heteroresistance associated with the gyrA and embB gene was 
also observed. 
 




Furthermore, the study discusses the implementation of the DOTS-Plus policy with regards to 
whether it significantly contributed to the emergence of XDR-TB in individual patients. 
Implications for implementation of standardized MDR-TB treatment in the absence of 
knowledge of baseline resistance are also discussed. 
 
Analysis of 48 MDR-TB patients, with initial and last available isolates, showed that 45,8% 
gained resistance to second line drugs during treatment which suggests that the combination 
of in-hospital treatment with a standardized MDR-TB treatment regimen increased the risk to 
the patient gaining XDR during treatment.  
 
This thesis has contributed to our understanding of drug resistance in TB, and implications of 
implementing standardized MDR-TB treatment in South Africa. We propose an algorithm for 
rapidly diagnosing patients that are at risk of extensively drug resistant tuberculosis (XDR-TB) 
using a combination of the methods endorsed by the World Health Organization (WHO). 
 






Suid-Afrika is ‘n land met stygende getalle middelweerstandige stamme van Mycobacterium 
tuberculosis. In 2000 is die DOTS-plus strategie oor die hele land ingestel om 
middelweerstandige tuberkulose (TB) te beveg. Dit het die bekendstelling van 
middelvatbaarheidstoetsing vir tweedeliniemiddels genoodsaak om gevalle tydig en effektief 
op te spoor en te behandel. Dit is egter eers in 2006, na die beskrywing van uitgebreide 
middelweerstandige (XDR)-TB, omskryf as MDR-TB plus weerstand teen fluorokinoloon en ’n 
tweedelinie inspuitbare middel as roetine geïmplementeer  in Suid-Afrika.  
 
Die impak van die implementering van 'n gestandaardiseerde MDR-TB-terapiebeleid op 
individuele behandelingsuitkomste en die opdoen van addisionele middelweerstandigheid in 
SA is nie goed gedokumenteer nie. Verbeterde kennis van die faktore wat tot die opdoen van 
tweedeliniemiddelweerstandigheid lei, sal lei tot beter voorspellings oor wie die hoogste risiko 
loop vir middelweerstandigheid, en ook bydra tot die ontwikkeling van nuwe middels en 
strategieë om MDR-TB te beveg. Ten einde hierdie gaping te vul, het ons probeer vasstel wat 
die voorkomssyfer van tweedeliniemiddelweerstandigheid onder MDR-TB-pasiënte in die 
DOTS-plus-studiegroep is en die uitwerking daarvan op behandelingsuitkomste vir hierdie 
pasiënte in twee provinsies in Suid-Afrika, naamlik die Oos-Kaap en Noordwes. 
 
Die resultate toon dat behandelingsukses sterk beïnvloed word deur die plek waar die 
pasiënte behandel is.  58.1% (193/333) van alle ongunstige uitkomste in die provinsies is te 
wyte aan versuiming van behandeling en sterfte. Die Oos-Kaap het die laagste 
genesingskoers (13.4%, 51/381) en die hoogste versuimingskoers (38.3%) gehad, in 
vergelyking met 'n versuimingskoers van 6.39% in Noordwes.  
 
Hierdie studie beskryf ook die weerstandspatrone teen tweedeliniemiddels onder nuut-
gediagnoseerde MDR-TB-pasiënte in Noordwes en die Oos-Kaap met genotipe-MTBDRsl-
toetsing (weergawe 1) en geteikende DNS volgordebapaling van gene bekend vir die oordra 
van weerstandigheid, en hoe hierdie pasiënte weerstand gedurende die behandeling opgebou 
het. Hierdie bevindinge het belangrike implikasies vir infeksiebeheer omdat 
ongediagnoseerde, hoogs weerstandige stamme na kontakte gedurende behandeling 
oorgedra kan word. Die ooreenstemming tussen die genotipe-MTBDRsl en DNS volgorde was 
82% vir al die gyrA-gene en 67% vir die rrs-geen. Weerstandigheid teen alle middels 
(insluitende etambutol) wat op aanvangsvlak getoets is, was 15.8% (47/298) en 
weerstandigheid teen sowel ofloksasien as kanamisien was 1.3% (4/298). 




Heteroweerstandigheid wat met sowel die gyrA-geen as die embB-geen geassosieer word, is 
ook waargeneem. 
 
Die studie bespreek verder die implementering van die DOTS-plus beleid en of dit  
betekenisvol aanleiding gee tot die verskyning van XDR-TB in individuele pasiënte. Die 
implikasies vir die implementering van gestandaardiseerde MDR-TB-behandeling met gebrek 
aan enige kennis oor aanvangsweerstandigheid, word ook bespreek. 
 
Die ontleding van 48 MDR-TB pasiënte, met ’n aanvanklike en ’n laaste kultuur toon dat 45,8% 
weerstand teen tweedeliniemiddels gedurende behandeling opgebou het. Dit dui daarop dat 
die kombinasie van behandeling in 'n hospitaal met ’n gestandaardiseerde behandelingsplan 
die risiko vir die pasiënt verhoog om XDR gedurende behandeling op te doen. 
 
Hierdie tesis dra by tot ons kennis oor en begrip van middelweerstandigheid in TB en die 
implikasies van die implementering van gestandaardiseerde MDR-TB-behandeling in Suid-
Afrika. Ons doen 'n algoritme aan die hand om pasiënte wat gevaar loop om uitgebreide 
middelweerstandige tuberkulose (XDR-TB) op te doen, vinnig te diagnoseer met 'n 
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In 2014, an estimated 9.6 million people developed tuberculosis (TB) and 1.5 million died from 
the disease, 400,000 of whom were HIV-positive.(1) The global TB rate has been falling by 
1.5% per year – far slower than the 10% yearly declines needed to end TB within twenty years. 
The African Region had 28% of the world’s TB cases, higher than the previously published 
estimate for 2012, accounting for 74% of people who are HIV positive. The global increase in 
drug resistance, particularly multidrug resistant TB (MDR-TB), is very concerning due to 
limited treatment options and much higher risk of death compared to drug susceptible TB. 
Only 50% of the MDR-TB patients who receive treatment survive. Of the estimated 480 000 
new cases of MDR-TB in 2014, a quarter (123 000) were reported as diagnosed. India, the 
Russian Federation and South Africa (SA) accounted for almost half of the total reported 
cases. Worldwide, 58% of previously treated patients and 12% of new cases were tested for 
drug resistance, up from 17% and 8.5% respectively in 2013. This improvement is partly due 
to the adoption of rapid molecular tests and improved reporting from laboratories.(2) MDR-TB 
is defined as TB that is resistant to isoniazid (INH) and rifampicin (RMP]), the two backbone 
drugs used in treat drug susceptible TB. According to the WHO Global Tuberculosis Report, 
the proportion of new cases with MDR-TB was 3.3%, and 20% of previously treated cases in 
2014, percentages that have changed little in recent years.(1) On average, an estimated 9.7% 
of patients with MDR-TB had extensively drug resistant TB (XDR-TB) defined as MDR-TB with 
additional resistance to any fluoroquinolone (FQ) and to at least one of three injectable 
second-line TB drugs (capreomycin [CAP], kanamycin [KAN] or amikacin [AM]).  
 
In 2016, the National Institute for Communicable Diseases (NICD) estimated MDR prevalence 
of 2.1% in new cases and 4.6% in retreatment cases with an overall, MDR-TB estimate of 
2.8% shifting from 2.9% in the previous survey 2001-02. (3)  Mpumalanga province showed 
the highest overall MDR estimate at 5.1%; notably higher than four other provinces: Eastern 
Cape 2.1%; Limpopo 1.6% North West 2.6% and Northern Cape 1.7%. The prevalence of any 
isoniazid resistance (9.3%) was higher than that of any rifampicin resistance (4.6%). The 
isoniazid mono-resistance levels were similar in new cases at 5.5% while in previously treated 
cases it was 6.5%. The TB-HIV co-infection rate was 63.2% nationally and highest in 
Mpumalanga 76.8%, followed by Gauteng 74.6%. The lowest rates were in the Western Cape 
and Northern Cape at 47.4% and 51.7% respectively. (3) Approximately 10.5% of MDR cases 




in South Africa have extensively drug-resistant tuberculosis (XDR-TB). (4-5) Studies have 
shown that the high mortality of XDR-TB patients in SA (41%-68%) is likely to be associated 
with a high level of HIV co-infection in TB patients. (1-2 5, 6) 
 
In 2013, Mycobacterium tuberculosis infections with even more complete resistance were 
identified. These isolates showed in-vitro resistance to all first and second–line drugs tested 
(13 drugs) and were subsequently termed totally drug resistant (TDR) or extremely drug 
resistant (XXDR) TB strains.(7-8) The patients infected with XDR and XXDR-TB have no 
reasonable treatment options and therefore may increase the risk of disease transmission 
among community contacts. There is evidence in South Arica that virtually untreatable strains 
of TB have become established and are circulating in the Eastern Cape Province and 
KwaZulu-Natal province of South Africa.(9) 
 
In KwaZulu-Natal, Max O'Donnell et al. presented outcomes for 114 adults treated for XDR-
TB at the provincial drug-resistant TB referral hospital in KwaZulu-Natal.(10) All cases started 
treatment between December 2006 and October 2007 and outcomes were ascertained from 
routine hospital records. Most were treated with a standardised regimen consisting of 
capreomycin (CAP), pyrazinamide (PZA), and p-aminosalicylic acid (PAS), ethionamide 
(ETO), ethambutol (ETH) and cycloserine (Cs) or terizidone (Trd). There was no laboratory 
data regarding drug susceptibility over and above the routine diagnostic tests used to identify 
the XDR-TB. Although culture remains the gold standard for TB and MDR/XDR-TB diagnosis, 
its complex requirements of laboratory infrastructure, equipment and personnel, as well as 
biosafety considerations and relatively long turnaround times, limit its potential for rapid 
diagnosis, especially in resource-limited settings. (11)  
 
Molecular techniques have provided new ways to study distribution of the mutation frequency 
and patterns and evolutionary genetics of the pathogen, which are all essential for effective 
control and prevention of TB. The Genotype MTBDRsl assay is the only rapid commercial test 
endorsed by the WHO for the detection of resistance to the main second-line drugs (SLD).(11) 
However, as this assay is limited to key commonly described mutations known to cause 
antibiotic resistance to second line drugs and do not allow the detection of new mutations, 
Direct Sequencing is used an alternative approach that allows for comprehensive detection of 
mutations associated with resistance to second-line anti-TB drugs.(12)  Furthermore, to gain an 
insight into the epidemiology of Mycobacterium tuberculosis isolates, several molecular tying 
methods are used e.g spacer oligotyping (Spoligotyping), IS6110-restriction fragment  length  
polymorphisms  (RFLP), and mycobacterial interspersed repetitive units-variable-number of 
tandem DNA repeats (MIRU-VNTR).(13)  Spoligotyping relies on identifying polymorphisms in 




the spacer units in the direct repeat (DR) region of the genome. This region contains multiple, 
conserved 36 base pairs (bp) DRs that have distinctive, individual spacer sequences that 
range from 34-41 bp in length spread between each DR. Spoligotyping has been used for  
rapid identification of laboratory error and contamination, and also establishing whether a 
strain is identical to or different from other strains found within a study community. (14-15)  When 
this principle is applied to serial isolates collected from a single patient, it is possible to relate 
the genotype of the infecting strain to the genotype of a strain from a prior episode of 
disease.(15)  Strains with shared genotypes are thought to represent ongoing transmission, 
while strains with unique genotypes are thought to represent reactivation.( 12) 
 
Spoligotyping provides some important advantages over other genotyping techniques. These 
are simplicity, rapidity, high reproducibility and stability of the results, with the latter being 
expressed in a simple digital pattern, readily named and databased. However, spoligotyping 
has relatively low discriminatory capacity for strains without a copy of IS6110 and also for 
those with a low copy number of less than six, which makes it necessary to use secondary 
fingerprinting methods to prove clonality between isolates. (16) Spoligotyping in combination 
with MIRU-VNTR has been used to replace RFLP-IS6110. (12)  
 
In Max O’Donnell’s study only one in five MDR-TB cases (22%) had a successful outcome 
(cure or completion) - 42% died, 17% defaulted and 19% failed treatment. Of the 42 cases 
with culture conversion during treatment, one in six showed culture reversion, suggesting the 
emergence of additional resistance during treatment because of lack of drug susceptibility 
testing for second line drugs to identify XDR-TB.(10) Similarly, Pietersen and colleagues 
prospectively followed 107 patients from three provinces in South Africa who had been 
diagnosed with XDR-TB between August 2002 and February 2008.(6) All were treated 
empirically as inpatients with a median of eight drugs. Genotypic testing of a subset of patients 
showed resistance to at least eight drugs. Fifty-six patients died in the hospital, six transferred 
out of the region, and 45 patients were discharged. Of those discharged into the community, 
19 had failed treatment and a third of those were smear positive at discharge. DNA 
fingerprinting showed that, in one instance, an XDR-TB patient who had failed treatment and 
was subsequently discharged, infected his brother who later died. (17) Together these studies 
clearly provide evidence that outcomes with standardised or empiric treatment regimens for 
XDR-TB are poor.    
 
  




1.2 RATIONALE OF THE STUDY 
 
Resistance to anti-TB drugs is a major challenge for TB control programs. This situation poses 
a serious problem for low income countries, especially those with a high prevalence of HIV. 
Another problem is that the MDR-TB treatment is lengthy, more difficult and the disease is 
costly to cure. Also, patients that are severely immunosuppressed by HIV infection have a 
lower response rate and higher fatality rate than HIV negative cases for MDR-TB treatment. 
The emergence of drug-resistant tuberculosis (DR-TB) is often attributed to the failure to 
implement proper TB control programs and to correctly manage TB cases.(5) The WHO reports 
that 218,231 RR-TB cases were from South Africa.(18) Molecular epidemiologic studies agree 
that the majority of new DR-TB cases SA are due to transmission of already resistant strains, 
rather than acquisition.(19) In contrast, XDR-TB appears to be acquired due to ineffective 
treatment of MDR-TB in some provinces and transmitted in others.(20-22) 
 
The Directly Observed Treatment (DOTS), short-course strategy was formulated by the World 
Health Assembly in 1991 and adopted by the South African National TB Control Programme 
in June 1996. DOTS comprises of five elements (i) fully supervised treatment with a 
standardized short-course regimen; (ii) case detection, with special attention to the use of 
sputum microscopy; (iii) reliable drug provision; (iv) effective monitoring of TB control 
programmes; and (v) government commitment to TB control. (23-24) Based on the Directly 
Observed Therapy (DOT) strategy, DOTS-Plus was designed to manage MDR-TB using 
second-line drugs. The DOTS-Plus (DP) strategy in SA consisted of the following: treatment 
at dedicated MDR-TB referral facilities, specialised teams overseeing all aspects of MDR-TB 
management at the referral centres, a standardised treatment regimen, regular monitoring of 
patients during treatment, extensive documentation, and ambulatory treatment after 
discharge, and patient follow-up for 5 years after treatment completion. In 2001, the South 
African national policy on MDR-TB recommended a standardised regimen of four to six 
months of kanamycin, pyrazinamide, ethambutol, ofloxacin and ethionamide during the initial 
intensive phase. This phase was followed by 12-18 months of ethambutol, ofloxacin and 
ethionamide in the continuation phase. Cycloserine was used as an ethambutol replacement 
when resistance to ethambutol was detected. The treatment guidelines were then revised 
during 2012 to recommend moxifloxacin (Mfx) instead of ofloxacin (Ofx). Referrals to MDR-
TB centres were based on either proven MDR-TB following sputum culture and susceptibility 
tests or clinical suspicion after failure of therapy. BACTEC 460 TB system (Beckton Dickinson, 
Sparks, MD, USA) was used as the gold standard, for both diagnosis and drug susceptibility 
testing (DST) of MDR-TB.  




In 2008 the GenoType MTBDRplus assay (MTBDR), which detects resistance to both INH 
and RIF within 48 hours, was endorsed by the WHO for the diagnosis of pulmonary TB 
(PTB).(21) The assay was implemented as a replacement for culture for the rapid detection of 
M. tuberculosis and drug resistance directly from sputum. The standard DST method for 
second line drugs was culture based—either conventional agar proportion or liquid. In 2011 
the WHO endorsed Xpert MTB/RIF assay was introduced as the primary method for rapid 
diagnosis of TB, replacing smear microscopy. Prior to this, the diagnostic tests available 
included the acid fast bacilli (AFB) smear (which miss half of active cases, especially in HIV-
coinfected patients), a chest X-ray (CXR) (which performs sub-optimally in HIV co-infected 
individuals) and mycobacterial culture and culture-based drug susceptibility tests for both first 
and second-line TB drugs. Culture was the gold standard for the diagnosis of MDR-TB, but 
the turnaround time is undesirably long (up to six weeks). The test was only performed on a 
subset of patients with high clinical suspicion for acquired resistance, and the resulting delays 
have an adverse impact on infection control.  
 
The development of efficient laboratory strategies for rapid and reliable antimicrobial 
susceptibility testing of M. tuberculosis is important for proper management of patients, 
particularly those with multidrug resistant tuberculosis. Traditional determination of drug 
resistance is by, three different growth based laboratory methods 
 
The success of the standardized regimen implemented by DOTS-Plus is dependent on how 
much additional resistance is present in MDR-TB patients at the baseline, for both the majority 
and potential minority strains.(22) If many patients have baseline resistance to drugs in the 
standardized regimen, then starting them on DOTS-Plus puts them on a weakened regimen. 
The impact of implementing the standardized MDR-TB therapy policy in South Africa on 
individual treatment outcomes and acquisition of additional drug resistance has not been 
evaluated. Improved knowledge of factors that lead to acquisition of second-line drug 
resistance will help better predict who is most at risk of drug resistance and contribute to the 
development of new tools and strategies to combat MDR-TB. To fill this knowledge gap, this 
thesis aimed to determine the prevalence of SLD resistance among MDR-TB patients in the 
DOTS-Plus cohort that were receiving treatment at dedicated facilities and its impact on 
treatment outcomes for these patients.  
 
1.3 OVERALL HYPOTHESIS 
 
A sub-optimal implementation of the DOTS-Plus in-hospital and standardized MDR-TB 
treatment regimen has led to emergence of extensively drug-resistant tuberculosis (XDR-TB). 




Certain M. tuberculosis strain lineages are more likely to acquire drug resistance and are 
associated with poor treatment outcomes.  
 
1.4 AIMS OF THE STUDY 
 
To 1) study the prevailing and evolving genetic characteristics (genetic fingerprints, mutations) 
and drug susceptibility profiles of sequential MDR-TB isolates infecting patients in two 
provinces in South Africa and 2) correlate these genetic characteristics with clinical outcomes 
associated with strain-specific M. tuberculosis infections.  
 
1.4.1 Primary Objectives  
 
The primary objectives of this study are to characterize consecutive serial isolates from MDR-
TB patients residing in two South African provinces and receiving hospitalized standardized 
MDRT-TB treatment. Our aims are:  
• To screen all MDR-TB isolates collected from a cohort of patients in the Eastern Cape and 
North-West Province for resistance to second-line anti-TB drugs (SLDs) and to identify 
their respective resistance profiles.  
• To describe changes over time in secondary drug resistance among MDR-TB patients. 
• To describe the prevalence of SLD resistance among MDR-TB patients in the DP cohort 
and its impact on clinically defined treatment outcomes. 
• To assess impact of implementing a standardized MDR-TB treatment regimen in two 
South African provinces. 
• To describe the prevalence of SLD resistance among MDR-TB patients in the DP cohort 
and its impact on treatment outcomes. 
 
1.4.2 Secondary Objectives 
 
These relate to clinical outcome and patient-related issues: 
• To determine if MDR-TB isolates with certain genotypes are more likely to acquire 
resistance to SLDs which are associated with poor outcomes (death, treatment failure, 
time to sputum negativity). 
• To determine whether certain MDR-TB genotypes irrespective of DST are linked to poorer 
clinical outcomes.  
• To determine the correlation between fingerprinting, drug susceptibility patterns, mutations 
and clinical outcome of a cohort of MDR-TB patients. 




• To investigate the occurrence of re-infections and mixed infections in a cohort of 264 MDR-
TB patients. 
 
1.4.3 This thesis is divided into the following chapters: 
 
I. Review: Phenotypic and genotypic techniques for the detection of extensively drug 
resistant tuberculosis (XDR-TB) (Chapter 2). I was responsible for the conceptual 
development and the collation of the literature and writing of the review. This chapter is 
prepared for submission to PloS One. 
 
II. Provincial differences in treatment outcomes of multidrug resistant tuberculosis patients 
under DOTS-Plus programme: A retrospective cohort study in two provinces of South 
Africa (Chapter 3). Clinical data was I was responsible for the conceptual design of the 
study, writing, statistical analysis with assistance from Sidney Atwood. This chapter is 
prepared for submission to PloS One. 
 
III. Detection of second-line drug resistance in Mycobacterium tuberculosis isolates Genotype 
MTBDRsl (version 1) assay and DNA sequencing (Chapter 4). Patient contact, sample and 
clinical data collection was done by the research team of the South African Medical 
Research Council. I was responsible the DNA extraction, Drug Susceptibility Testing of 2nd 
line drugs and analysis. DNA samples were sent to the University of Stellenbosch 
Sequencing Lab for sequencing, with laboratory advice and assistance from Dr Lizma 
Streicher. 
 
IV. Emergence of additional drug resistance during standardized MDR-TB treatment (Chapter 
5). The gene mutation data was sourced from chapter 4, analysis and writing was my 
resposnsibility. I was responsible for most of the Spoligotyping experiment with laboratory 
advice and assistance from Dr Lizma Streicher. This chapter is prepared for submission 
to the International Journal of Tuberculosis and Lung Disease. 
 
V. Characteristics and treatment outcomes of patients with multidrug resistant tuberculosis in 
South Africa (Chapter 6). Clinical data collection was done by the research team of the 
South African Medical Research Council. I was responsible for writing and analysis with 
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REVIEW: PHENOTYPIC AND GENOTYPIC TECHNIQUES FOR THE 





Background: Tuberculosis remains a global problem due to several reasons including 
inadequate treatment programmes, the HIV epidemic, increasing economic deprivation, lack 
of laboratory capacity and the emergence of drug resistant TB (DR-TB). Early and accurate 
diagnosis of drug resistance in TB is important so that effective treatment is provided as soon 
as possible to ensure rapid cure. In this review, we discuss the mechanisms of second line 
drug resistance, strategies for determining drug resistance and implementation of molecular 
TB diagnostic tests. 
 
Objectives: To propose an algorithm for implementation of one or a combination of the 
methods endorsed by WHO for rapid identification of second-line resistance and thereby XDR-
TB in a high TB and HIV burden country. 
 
Results: The accuracy of sequencing by pyrosequencing is comparable to that of Sanger 
sequencing. Despite the simplicity, low cost, and relative rapidity of pyrosequencing, results 
still have to be confirmed by a phenotypical culture-based method for correct management of 
XDR-TB. 
 
Conclusions: More than one method is needed because phenotypic methods do not satisfy 
the requirement of rapid results and genotyping is a better alternative for rapid detection of 













2.2  INTRODUCTION  
 
Tuberculosis remains a serious global health challenge as a result of several reasons including 
inadequate treatment programmes, the HIV epidemic, increasing economic deprivation and 
the emergence of drug resistant TB (DR-TB). DR-TB develops either due to infection with a 
resistant strain (transmitted), or as a result of inadequate treatment (acquired), for example 
when a patient receives a weak treatment regimen, is given poor quality drugs or has 
malabsorption of medications.(1-3) Non-compliance has been cited as the main contributor to 
the burden of drug resistance TB. From a patient perspective, lack of money to pay for 
transportation, long distance from clinics, negative attitudes from the healthcare providers 
discourages the patients from treatment adherence. (4-5) Lack of information, stigma, side-
effects of drugs and poor integration of TB-HIV services plays its share in poor treatment 
adherence. (6) Poor knowledge about TB and the efficacy of treatment beginning of their 
treatment also has a share. (7) 
 
Years of issues with care delivery has led to the emergence of virtually untreatable forms of 
TB, now termed extensively drug-resistant tuberculosis (XDR-TB), defined as resistance to at 
least isoniazid (INH) and rifampicin (RIF) also known as multidrug-resistance (MDR-TB), and 
in addition, to any fluoroquinolones (FQs) (such as ofloxacin or moxifloxacin) and to at least 
one of three injectable second-line drugs (amikacin (AM), capreomycin (CAP ) or kanamycin 
(KAN)).(8-9) This review will discuss the mechanisms of second-line drug resistance, strategies 
for determining drug resistance and implementation of molecular TB diagnostic tests. The 
following section is focused on epidemiology of XDR-TB, diagnostic and treatment challenges 
of XDR-TB. 
 
Globally, 4 044 patients with XDR-TB were enrolled in treatment in 2014 (an increase from 
3 284 in 2013).(10) Although the reporting of data has improved since 2008, XDR-TB 
prevalence is still believed to be underestimated because most countries have limited ability 
to perform drug susceptibility testing (DST) for second-line drugs. Because many cases of 
XDR-TB are never diagnosed, let alone properly treated, they remain high risk for on-going 
propagation of the epidemic. Most cases of MDR-TB and XDR-TB in South Africa have been 
detected in KwaZulu-Natal, the Western Cape, and Eastern Cape Provinces. In 2009, the 
respective figures of patients diagnosed were 1,773; 2,078; 1,858 for MDR-TB and 254; 72 
and 123 for XDR-TB. (11) In South Africa, the number of people with TB initiating treatment 
decreased from 406 082 to 332 170 between 2009 and 2013. However, during the same 
period, the number of patients who initiated treatment for MDR-TB more than doubled, from 4 
143 to 10 179, with a 45% treatment success rate.(11) The treatment success rate of XDR-TB 




was between 15% and 20%.(7) Reasons for the poor treatment outcomes are many, including 
poor linkage and retention to care, poor tracing mechanisms and limited access to new agents 
for example bedaquiline and linezolid. The recent discovery of a totally drug-resistant TB in 
the Eastern Cape raises the concern that untreatable strains will soon spread more widely. 
This new strain has shown resistance to at least 10 anti-TB drugs currently in use in the public 
health sector.(12) 
In order to respond to the dual epidemics of HIV and TB, SA developed an integrated National 
Strategic Plan (NSP) for HIV, STIs and TB (2012 - 2016).(13) One of the goals of the NSP was 
to reduce the number of new TB infections and deaths from TB by half by 2016. Among the 
strategies to achieve these goals are: 1) Intensified Case Finding (ICF); 2) TB infection control; 
3) workplace health policies on TB and HIV; 4) provision of IPT; 5) prevention of MDRTB; and 
6) reduction of TB-related stigma. In addition, the strategic plan prioritizes testing and 
screening for HIV and TB, improved contract tracing, early diagnosis and rapid enrolment into 
treatment and integration of HIV and TB care in the healthcare system.(13) To achieve these 
targets, in 2011 the National Tuberculosis Programme (NTP) recommended ambulatory over 
hospital-based treatment for MDR-TB cases in order to achieve rapid diagnosis and treatment 
initiation.(14)  
 
Definitive diagnosis of MDR-TB and XDR-TB requires that M. tuberculosis be isolated and 
identified, and drug-susceptibility testing (DST) completed.(15) Using conventional 
methodologies, including growth detection, identification of M. tuberculosis and DST for first 
and second-line drugs, may take eight to twelve weeks. Because delays in diagnosis and 
treatment can lead to poor individual outcomes and increased spread of disease, the WHO 
and partners have proposed a global XDR-TB response plan, calling for implementation of 
rapid methods to screen patients at risk of rifampicin resistant-TB.(16) Rapid tests can provide 
results within days (even without culture, i.e. directly on specimens) and thus enable prompt 
and more appropriate treatment, decrease morbidity and mortality and interrupt transmission. 
Treatment of MDR-TB is difficult due to delayed diagnosis and, once identified, ineffective 
drugs that are more costly, toxic and lengthy than drug susceptible therapies. MDR-TB 
treatment regimens ideally include five drugs and lasts for 18-24 months. In South Africa, 
fluoroquinolones and injectable aminoglycosides are the two backbone drugs used in MDR-
TB treatment. From 2010, ethambutol was replaced by cycloserine (Cs) or terizidone (Trd).(17)  
 
Since 2008, much attention has been given to rapid techniques for second-line drug 
susceptibility. Currently available rapid tests to detect XDR-TB are Line Probe Assay, 
Pyrosequencing, Whole Genome Sequencing, and Reverse Line Hybridization Assay (see 
Table 2.).(18-22) The expense and technical requirements involved in these PCR tests puts them 




out of reach of most patients in TB-endemic countries. The high risk of transmission of TB 
makes cost-effective and rapid detection crucial to control the spread of infection.(23) The WHO 
has endorsed commercial rapid liquid TB culture methods.(24) and two molecular assays(25) for 
simultaneous detection of both M. tuberculosis and resistance to isoniazid (INH) and or 
rifampicin (RIF).  Although several drugs are mentioned per class, only one of them needs to 
be tested because of cross-resistance between members of that class.(26) In 2009 the WHO 
endorsed the use of Genotype MTBDRsl assay for the detection of resistance to second-line 
anti-tuberculosis drugs to rule out XDR-TB, but it cannot be used to define XDR-TB for 
surveillance purposes. This assay significantly improves diagnostic yield while simultaneously 
decreasing diagnostic delay for reporting second-line DST.(25)  Limitations of Genotype 
MTBDRsl are that there is incomplete cross-resistance between the second-line injectables, 
and the assay does not allow for specific resistance to individual second-line injectables to be 
determined.(27) 
 
It was therefore imperative to develop, improve and evaluate diagnostic methods to rapidly 
identify second-line resistance and thereby XDR-TB. This review will focus on the most 
promising currently available diagnostic techniques and will highlight strengths and 
weaknesses of the different assays. An algorithm will be proposed for the implementation of 
one or a combination of the methods endorsed by WHO into a routine program of a high TB 
and HIV burdened country and how healthcare professionals can adapt to use and interpret 
the results.  
 
The emergence of XDR-TB continues to threaten national TB programmes around the world. 
Drug resistance most often develops when first- or second-line TB drugs are misused or 
mismanaged (when patients do not take the full course of treatment or doctors prescribe the 
wrong dosage, duration or drugs for treatment) and thereby become ineffective and also due 
to person to person transmission. The XDR M. tuberculosis strains are more likely than the 
non–XDR MDR strains to be clustered, suggesting that transmission plays a critical role in the 
new incidence of XDR-TB.(26)  In contrast, findings by Ioerger et al. suggest that XDR drug 
resistance in the Beijing strains in the Western Cape is not spreading clonally, but continues 
to be acquired independently in different strains.(28) XDR-TB infection is particularly 
problematic for individuals with HIV or other conditions weakening the immune system. 
Patients who are coinfected with HIV have varying degrees of intestinal absorption of TB 
drugs(29,30) and of treatment failure with standard regimens,(31, 32) both of which potentially 
increase the risk of acquiring or amplifying TB drug resistance.(33) Treating XDR-TB 
successfully is difficult, because of the lengthy treatment duration of 18–30 months, and 
the difficulty in tolerating side effects and toxicities of second-line medications.(28)  





In 2005, large numbers of patients with MDR-TB and XDR-TB were identified at a rural hospital 
in Tugela Ferry, KwaZulu-Natal. Systematic surveillance undertaken at the hospital between 
January 2005 and March 2006 revealed that, of 542 patients with positive sputum TB culture 
results, 221 (41%) had MDR-TB and 53 (10%) had TB caused by M. tuberculosis strains with 
resistance to all six drugs tested (isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, 
and kanamycin).(12) The mortality rate among patients with XDR-TB was 98% most of whom 
were co-infected with HIV, with a median survival time of 16 days from the time of collection 
of diagnostic sputum samples.(34) By year-end 2008, XDR-TB cases diagnosed in Tugela Ferry 
had increased to 463, though the mortality rate had fallen to 82% and most patients had a 
median survival time of 28.5 days after sputum collection.(35) Available data from different 
studies shows that treatment duration is longer and outcomes are generally poorer for XDR-
TB, compared with patients with MDR-TB. However, an observational cohort study by Sotgiu 
et al. showed that XDR-TB can be successfully treated in up to 65% of patients, with better 
outcomes for those not coinfected with HIV. (36) According to a review study by Jacobson et al. 
the proportion of patients who experience favourable outcomes is in the range of 18% to 67%, 
and the percentage of patients who received a later-generation fluoroquinolone was 
significantly associated with the proportion with favourable outcomes. (37) These studies also 
suggest that patients receiving later-generation fluoroquinolones have a 40% increase in 
favourable outcomes, compared with patients not receiving later-generation fluoroquinolones. 
(37) 
 
2.3  MECHANISMS OF SECOND-LINE DRUG RESISTANCE 
 
2.3.1  Fluoroquinolones 
 
The most common mechanisms by which bacteria acquire resistance to fluoroquinolones is 
by spontaneous mutations in chromosomal genes that alter the structure of gyrase or 
topoisomerase IV or both. Resistance mutations occur in the DNA gyrase gene encoding two 
short discrete segments termed the quinolone resistance-determining regions (QRDR) of 
GyrA subunit (QRDR-A) and less frequently in GyrB (QRDR-B), respectively.(33) Specific 
amino acid substitutions and the number of resistance mutations in the QRDR lead to the 
development of different levels of fluoroquinolone resistance. Individual mutations in gyrA may 
confer low-level resistance (MIC < 2 mg/L),(34) while high-level (MIC 6.0, 8.0 and 10.0 mg/L) 
resistance to fluoroquinolones usually requires multiple mutations in gyrA, or concurrent 
mutations in gyrA and gyrB.(22) Asp94Gly substitutions in the gyrA gene are associated with 




high level OFX resistance (35) rendering the DNA gyrase protein conformation more difficult for 
fluoroquinolones to bind to, resulting in higher MIC values.  
From the earlier studies, DNA sequencing of gyrA showed that certain strains possessed a 
naturally occurring polymorphism at codon 95 (Ser95Thr), which did not have a significant 
impact on fluoroquinolone susceptibility as it occurs in both fluoroquinolone-susceptible and 
fluoroquinolone-resistant strains. Instead, mutation at codon 95 of gyrA gene serves as an 
evolutionary marker for classification of Mycobacterium tuberculosis strains into Principal 
Genetic Groups (PGG).(25,26)  Group 1 has the allele combination katG codon 463 CTG (Leu) 
and gyrA codon 95 ACC (Thr); group 2 has katG 463 CGG (Arg) and gyrA codon 95 ACC 
(Thr), and group 3 organisms have katG 463 CGG (Arg) and gyrA codon 95 AGC (Ser).(36) 
 
Studies have also shown that mutations in the QRDR region of gyrA account for 42–100% (37-
39, 35) of fluoroquinolone resistance, suggesting that there could be other alternative 
mechanisms of resistance like efflux pumps, which export toxins out of the cell thereby 
reducing the intracellular concentration resulting in low level resistance.(40) Several 
mycobacterial efflux pumps associated with FQs resistance have been described. These 
efflux pumps include the pumps of the Major Facilitator Superfamily (MFS) family (lfrA, Rv1634 
and Rv1258c) and ATP Binding Cassette (ABC) transporters (DrrAB, PstB and Rv2686c-
2687c-2688c). (41) In addition to the two efflux pumps mentioned above, numerous efflux 
determinants of fluoroquinolone resistance in mycobacteria have been described. (42-43) A 
further explanation for the absence of a correlation between FQ resistance and gyrA mutation 
is the occurrence of FQ heteroresistance. Some studies reported between 22 and 31% of 
patients being infected with both wild-type and QRDR mutant M. tuberculosis strains.(36,33,44) A 
systematic review study by Avalos et al. showed A90V as the most frequent, followed by D94G 















Table 1: The cumulative frequencies of gyrA point mutations in FQ resistant isolates in  































A90V 280 258 65 0 0.33 0 
D94G 280 258 92 0 0.23 0 
D94A 280 258 30 0 0.11 0 
D94N 280 258 27 0 0.10 0 
S91P 280 258 15 0 0.05 0 
D94Y 280 258 2 0 0.01 0 
G88C 275 250 3 0 0.01 0 
Source Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, et al. Frequency and Geographic Distribution of 
gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium tuberculosis Isolates: A 
Systematic Review. PLoS One. 2015; 10. 
 
Fluoroquinolone resistance due to gyrB mutations was thought to be rare, however, clinical 
isolates resistant to FQs with gyrB mutations and wild type (WT) gyrA loci have been reported 
in several studies.(43-45) GyrB mutations at amino acid positions Arg-485, Asp-495, Asn-510, 
Thr-511, Arg-516 Asn-533, Asn-538 and Ala-54 have been reported.(44-46,48-50) 
 
Although ofloxacin is commonly used because of its relatively lower cost, moxifloxacin (a later-
generation fluoroquinolone) is more effective than ofloxacin for patients with MDR-TB, even 
with ofloxacin-resistant strains.(51) Moxifloxacin is a synthetic, broad spectrum 8-methoxy 
fluoroquinolone antibacterial agent which has shown high bioavailability, a good curative 
effect, lower MICs and minimal adverse effects.(41, 51-52) This has led WHO to recommend 
substituting moxifloxacin when there is resistance to early generation fluoroquinolones like 
ofloxacin and ciprofloxacin.(53) It targets the mycobacterial topoisomerase II DNA gyrase and 
blocks the movement of replication forks and transcription complexes. It is active against 
strains with low levels of resistance (MIC, 0.5 μg/ml) and reduces the mortality associated with 
strains with intermediate resistance (MIC, 2 μg/ml). (51) However, it is inactive, against strains 
with high levels of resistance (MIC, >2 μg/ml). (51) 
 
2.3.2  Aminoglycosides 
 
Kanamycin and amikacin are injectable aminoglycosides used in the treatment of multidrug 
resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). These 
drugs are more toxic, less effective and more costly than the standard anti-TB regimen. They 
are considered as a reserve therapy and are used when patients are intolerant to first-line 
drugs or cannot take first line drugs.(53) 




Aminoglycosides inhibit protein synthesis by binding to the 16S rRNA in the 30S ribosomal 
subunit.(54) Resistance develops through mutation in the rrs gene at position A1401T and 
G1484T, thereby altering the binding between the aminoglycoside and the 16srRNA (∼1,400-
bp) with high-level resistance MICs of ≥80 μg/ml.(47-57 ) High level kanamycin resistant strains 
are also cross resistant to other ribosome binding antibiotics including capreomycin and 
amikacin.(58) In contrast, low-level KAN-resistant (5 μg/ml < MIC < 80 μg/ml) strains generally 
exhibit resistance to KAN only. More recently, studies have shown that mutations in the eis 
promoter are associated with KAN resistance. Zaunbrecher found that up to 80% of strains 
showing low-level KAN resistance harboured mutations in the -10 and -35 promoter region of 
the aminoglycoside acetyltransferase gene eis.(56) The KAN resistance conferred by eis 
promoter mutations is due to the significant increase in eis transcript levels and corresponding 
increase in the levels of an enzyme that acetylates and inactivates KAN.(56) 
 
2.3.3  Ethionamide  
 
Ethionamide is a derivative of isonicotinic acid structurally similar to isoniazid. It is also a pro-
drug requiring activation by a monooxygenase encoded by the ethA gene. It interferes with 
the mycolic acid synthesis by forming an adduct with NAD that inhibits the enoyl-ACP 
reductase enzyme.(59) ethA expression is regulated by the transcriptional repressor EthR.(60) 
Resistance to ethionamide occurs because of mutations in etaA/ethA, ethR and also mutations 
in inhA promotor, which cause resistance to both isoniazid and ethionamide.(61-62) 
Consequently, cross-resistance to these two antibiotics has been observed in clinical 
isolates.(63) Strains with low-level resistance to INH frequently display low-level ethionamide 
resistance, whereas high-level INH-resistant strains typically remain ethionamide 
susceptible.(64) In the case of low-level resistance to INH, patients may benefit from high doses 
of isoniazid instead of ethionamide.(65) 
 
2.3.4  Pyrazinamide 
 
Pyrazinamide is an analogue of nicotinamide and its introduction into the regimen allowed a 
reduction in the duration of treatment to six months.(59) It has the characteristic of inhibiting 
semi-dormant bacilli residing in acidic environments such as those found in the TB lesions.(66) 
Pyrazinamide is also a pro-drug that needs to be converted to its active form, pyrazinoic acid, 
by the enzyme pyrazinamidase/nicotinamidase coded by the pncA gene.(67) The proposed 
mechanism of action of pyrazinamide involves conversion of pyrazinamide to pyrazinoic acid, 
which disrupts the bacterial membrane energetics inhibiting membrane transport.(68) 
Pyrazinamide would enter the bacterial cell by passive diffusion and after conversion to 
pyrazinoic acid it is excreted by a weak efflux pump. Under acid conditions, the protonated 




pyrazinoic acid would be reabsorbed into the cell and accumulated inside, due to an inefficient 
efflux pump, resulting in cellular damage.(69) One study has also found that pyrazinoic acid 
and its n-propyl ester can inhibit the fatty acid synthase type I in replicating M. tuberculosis 
bacilli.(70)  
 
Mutations in the gene pncA remain as the most common finding in pyrazinamide resistant 
strains. These mutations are scattered throughout the gene, however most occur in a 561-bp 
region in the open reading frame or in an 82-bp region of its putative promoter.(71) The study 
review by Whitfield et al. reported that SNPs are distributed throughout the entire pncA gene, 
with more than 600 unique polymorphisms observed in approximately 400 positions in pncA 
(including the upstream flanking region).(72) Shi et al. confirmed that the ribosomal protein S1 
(RpsA), encoded by the rpsA gene, was a target of POA which might be associated with PZA 
resistance in clinical M. tuberculosis isolates. However, based on the current evidence, the 
contribution of mutations in rpsA to pyrazinamide resistance remains limited. (73-75)   
 
2.4  DRUG SUSCEPTIBILITY TESTING  
 
In general, there are two different strategies for determining drug resistance; the phenotypic 
and genotypic/molecular methods. The phenotypic susceptibility testing is based on the 
determination of growth or inhibition of growth in the presence of antibiotics, whereas 
molecular methods detect gene mutations that are known to be associated with resistance to 
certain antibiotics. Drug susceptibility testing (DST) of M. tuberculosis is generally carried out 
after a culture is isolated from a clinical specimen. This takes four to six weeks, first to isolate 
a culture and then to perform drug susceptibility testing (indirect DST). Specimens for culture 
methods have to be decontaminated prior to being cultured to prevent overgrowth by other 
micro-organisms. All decontamination methods are to some extent also harmful to 
mycobacteria, and the culture is therefore not 100% sensitive.(76) Phenotypic tests are also 
greatly affected by the inoculum size as well as the viability of the strains. 
 
2.4.1 Phenotypic second-line drug susceptibility testing 
 
Second-line DST for certain drugs has not been standardized throughout the world, due to 
technical difficulties related to in vitro drug instability, drug loss caused by protein binding, heat 
inactivation, filter sterilization, incomplete dissolution and/or varying drug potency.(77) 
Laboratory technique, medium pH, incubation temperature and incubation time also influence 
DST results.(77) In addition, the drug critical concentration defining resistance is often very 
close to the minimal inhibitory concentration (MIC) required to achieve antimycobacterial 




activity, increasing the probability of misclassification of susceptibility or resistance, and 
leading to poor reproducibility of DST results.(48) For M. tuberculosis, the antimicrobial 
susceptibility testing breakpoint (also known as the "critical concentration") is defined as "the 
lowest concentration of drug that will inhibit 95% of wild strains of M. tuberculosis that have 
never been exposed to drugs, while at the same time not inhibiting clinical strains of M. 
tuberculosis that are considered to be resistant (e.g. from patients who are not responding to 
therapy)".(78) 
 
Internationally, few laboratories have the required capacity and expertise to reliably test for all 
classes of available anti-TB drugs. These laboratories are largely limited to resource-rich 
settings. Newer phenotypic techniques aim for a more rapid detection of growth by using the 
metabolic activities of growing bacteria.(79). These techniques, namely automated liquid culture 
systems, are difficult to implement in the countries where they are most needed owing to high 
cost, technical complexity and lack of appropriately trained laboratory staff. As a result, 
conventional culture and DST methods using egg-based or agar-based media are still the 
most widely used in resource-limited settings, leading to long diagnostic delays.  Even in 
sophisticated and well-resourced environments, wide variations in second-line DST systems 
and methods have been reported, reflecting the difficulties in securing reproducibility and 
optimizing the clinical relevance of DST results. (15) 
 
Rapid liquid culture-based techniques have been established that can detect growth-
dependent changes such as oxygen consumption (Mycobacteria Growth Indicator Tube 
[MGIT] (Becton-Dickinson, Sparks, MD) and VersaTREK (Trek Diagnostic systems, West 
Lake, OH).(80)  Furthermore, a more rapid detection of growth can also be achieved by 
microscopic observation of liquid cultures in tissue-culture plates (microscopic-observation 
drug-susceptibility [MODS] assay). Since mycobacteriophages are able to only replicate in 
living cells, phage-based tests have also been developed for speeding up DST. (81)  
 
There are several drugs used to treat MDR-TB for which drug susceptibility testing (DST) is 
desired. The comparisons of different detection methods (both phenotypic and molecular) for 
XDR-TB are discussed in Table 2. Below is a list of WHO approved phenotypic tests for 
identification of drug resistance.  
 
a) BACTEC MGIT 960 system: The diagnostic method endorsed by the World Health 
Organization (WHO) as a gold standard for the diagnosis of XDR-TB is the automated 
liquid systems (BACTEC MGIT 960 system). The BACTEC MGIT 960 system is an 
automated continuously monitoring system, based on the detection of bacterial growth in 




drug-containing media which is compared to a drug-free control tube.(82) A modified version 
of the conventional modified agar proportion method (MOP) has been developed for this 
system, in order to test the susceptibility of M. tuberculosis to the second-line drugs.(78) 
Although it is still technically demanding, it significantly shortens turnaround times for 
DSTs compared to conventional methods on solid media. The average reporting time for 
the DST results ranges from five to seven days for the BACTEC MGIT 960 system and 
two to four weeks using the conventional Löwenstein-Jensen medium.(83) However, 
currently no commercially available kit exists.(84) This makes it more error-prone as the 
working solutions of each drug should be prepared by the users and could lead to 
procedural inaccuracies. Other drawbacks of this test include i) it is labour-intensive with 
regards to the handling of vials and maintenance of the instrument, and (ii) there is a 
potential risk of cross-contamination of the cultures. Automated liquid systems for second-
line DST are more prone to contamination and the manipulation of large volumes of 
infectious material requires appropriate and adequate biosafety measures.(85) 
 
b) Agar Proportion Method: The proportion method consists of calculating the proportion of 
resistant bacilli present in an isolate. Two appropriate bacillary dilutions, one high and one 
low, are inoculated on a drug containing and drug free medium, in order to provide 
numerable colonies on both agar media reference.(84)The ratio of the number of colonies 
obtained on the drug containing medium to the number of colonies obtained on the drug 
free medium indicates the proportion of resistant bacilli present in the strain.(86) The isolate 
is resistant if more than 1% of the number of colonies on the control agar growth is visible 
on the drug agar plate. This method is time consuming, requiring up to two months for the 
results to be obtained. This may lead to substantial delays in the identification and 
treatment of MDR-TB patients, and may also contribute to MDR-TB transmission in 
communities. 
 
c) Nitrate Reductase Assay (NRA): The NRA, also known as the Griess method, is a simple 
technique based on the capacity of M. tuberculosis to reduce nitrate to nitrite. By 
incorporating 1 mg/ml potassium nitrate (KNO3) in a Lowenstein–Jensen medium, the 
reduction of nitrate can be detected using the Griess reagent, which produces a coloured 
reaction.(87) In the presence of an antibiotic at the critical concentration, development of a 
red–pink colour in the medium represents resistance. Susceptible strains lose the capacity 
to reduce nitrate in the presence of the antibiotic, thus no colour is produced. The use of 
nitrate reduction as an indicator of growth, before colonies can be seen macroscopically, 
reduces the turnaround time to achieve results compared to conventional methods. The 
WHO recommends that the NRA be used as a direct test on smear-positive sputum 




specimens or as an indirect test on M. tuberculosis isolates grown from a conventional 
solid culture.(88) Data also shows that the sensitivity of NRA to second-line drugs is 100% 
and the turnaround time is 10 to 14 days.(89) NRA is simple, cost-effective and the use of 
solid media minimises cross-contamination and biohazard risks. It requires less 
sophisticated equipment and is a method of choice in resource limited countries.  
 
2.4.2 Molecular Methods 
 
These methods search for the genetic determinants of resistance rather than the resistance 
phenotype. In general, they have two basic steps: a molecular nucleic acid amplification step 
such as PCR to amplify sections of the M. tuberculosis genome known to be altered in resistant 
strains, and a second step of assessing the amplified products for specific mutations.(90)  
 
Current molecular methods for detection of genetic mutations associated with second-line 
resistance include second-generation LPAs, pyrosequencing and targeted sequencing which 
offer an alternative to the conventional methods. However, only a few mutations conferring 
resistance have been described for most second-line drugs and testing is technically 
demanding and expensive.  
 
a) Line Probe Assay: The GenoType MTBDRsl (version 1) that was released in 2009, allows 
the simultaneous detection of the M. tuberculosis complex and resistance to fluoroquinolones, 
aminoglycosides or ethambutol on TB bacteria grown in culture from a patient specimen, 
therefore allowing the rapid detection of XDR-TB (91) and can be used in combination with the 
MTBDRplus test to identify XDR-TB. The major advantage of Genotype MTBDRsl assay is 
that the test can also be directly applied to smear-positive sputum samples, giving rapid drug 
susceptibility results without the need for culture. It detects the presence of mutations in genes 
that cause drug resistance to fluoroquinolones, or second-line injectable drugs, or both. 
However, it does not report whether there is resistance to individual drugs within these 
categories (ofloxacin and levofloxacin in the case of the fluoroquinolones; amikacin, 
kanamycin, and capreomycin in the case of second-line injectable drugs) but detects the 
presence of mutations in genes that cause drug resistance for drug classes (ie FQs, second 
line injectable drugs (SLIDs) or both). (92)  
 
Findings from several studies have shown that Genotype MTBDRsl assay has the poorest 
sensitivity for kanamycin resistance.(93-94) In line with this observation, Huang et al showed that 
the low sensitivity of Genotype MTBDRsl assay was due to the presence of specific mutations 
not detected by the test, located in the eis gene promoter region.(95) These mutations are 




responsible for more than 80% of low-level KAN resistant cases,(96) making this genetic region 
a valuable molecular marker of KAN resistance. The disadvantages of LPA’s are that they are 
labour intensive and require highly trained personnel and dedicated laboratory space. Another 
limitation is that only a limited number of mutations can be detected with a single test. Thus, 
in cases where the mutations are outside of the targeted regions, the wild-type banding 
patterns appear, leading to false negative (susceptible) results.  
 
To improve the overall performance of Genotype MTBDRsl, and in particular its sensitivity for 
KAN resistance, a new version of the assay (i.e. Genotype MTBDRsl v2.0) has recently been 
developed.(97) 
 
Genotype MTBDRsl v2.0 includes two new target genetic regions: the eis promoter region −10 
to −14 (in addition to rrs) and the gyrB quinolone resistance-determining region (QRDR) (in 
addition to gyrA) for the detection of mutations at codons 536 to 541. The target region for 
emb (embB) has been removed. Genotype MTBDRsl v2.0 thus includes a total of 27 probes 
for the detection of resistance exclusively to second-line drugs. The inclusion of probes for the 
detection of mutations in the eis promoter region increased the overall sensitivity of Genotype 
MTBDRsl v2.0 for the detection of SLID resistance to 86.4% (95% CI, 79.9% to 91.0%) and 
the sensitivity for the detection of kanamycin resistance to 96% for both the isolates and the 
clinical specimens, which is higher than the pooled sensitivity values for Genotype MTBDRsl 
v1.0 (66.9%; 95% CI, 44.1% to 83.8).(98) 
 
The inclusion of probes for the detection of mutations in the eis promoter region in the 
Genotype MTBDRsl v2.0 test has resulted in a higher sensitivity for detection of kanamycin 
resistance for both direct and indirect testing (96% and 95.4%, respectively) than that seen 
with the original version of the assay.  The test sensitivities for detection of FLQ resistance 
remained unchanged (93% and 83.6% for direct and indirect testing, respectively). Moreover, 
Genotype MTBDRsl v2.0 showed better performance characteristics than v1.0 for the 
detection of XDR-TB, with high specificity and sensitivities of 81.8% and 80.4% for direct and 
indirect testing, respectively. Genotype MTBDRsl v2.0 thus represents a reliable test for the 
rapid detection of resistance to second-line drugs and a useful screening tool to guide the 
initiation of appropriate MDR-TB treatment.(99) 
 
b) DNA sequencing: This method is based on DNA sequencing technology using the chain-
termination method. While DNA sequencing of variable genomic regions offers a rapid and 
accurate identification of mycobacteria, this method is not yet practical for use outside 




academic settings and is too expensive for most resource-poor countries. Streicher et al. 
have demonstrated that targeted DNA sequencing is also suitable for clinical trials. (100) 
  
c) Pyrosequencing: Pyrosequencing (PSQ) is a semi-automated sequencing method based 
on real-time monitoring of DNA synthesis, optimized to analyse short DNA sequences. It 
is based on the quantitative detection of released pyrophosphate during DNA synthesis. 
In a cascade of enzymatic reactions, light is generated at intensities proportional to the 
numbers of incorporated nucleotides.(101) PSQ has a short turnaround time and is less 
hands-on and easier to handle than conventional sequencing method.(102) The entire 
procedure, from extracting DNA to reporting results, can be accomplished within six hours 
using a protocol that can be easily integrated into the workflow of diagnostic or public 
health laboratories. Although this method is easier to perform and less expensive than 
traditional sequencing, the shorter sequences are not as discriminating. It cannot be 
practically applied when mutations are spread widely over a gene, as is the case in pncA. 
It is therefore difficult to use for pyrazinamide resistance detection.(103) By using automated 
sequencers and well-trained staff, sequencing assays can be completed and identification 
results can be reported within one to three days. However, the installation, maintenance 
and running of automated DNA sequencing on a daily basis are currently too expensive 
and labour-intensive for use in resource poor settings.(104) 
 
d) Targeted Next-Generation Sequencing (NGS): In contrast to Pyrosequencing, NGS allows 
interrogation of many genes with sequencing of much longer segments in a relatively short 
time, but requires sophisticated software to handle huge data sets. NGS has vastly 
improved nucleic acid sequencing with respect to amount, speed and cost of data 
obtained.(105) Unlike conventional sequencing techniques, it is based on the immobilization 
of the DNA samples onto a solid support, cyclic sequencing reactions using automated 
fluidics devices and detection of molecular events by imaging.(106) In contrast to most 
Sanger sequencers, the Ion Torrent does not utilize (expensive and maintenance-
requiring) lasers that typically require modified fluorescence-based, light-sensitive 
chemistries and it has a much smaller overall footprint. The current NGS platforms need 
higher DNA concentrations (>50 ng), necessitating growth from cultures for testing. 
Colman et al have found out that the use of “single molecule-overlapping reads” (SMOR) 
analysis with next generation DNA sequencing for determination of ultra-rare target alleles 
subpopulations at (≥0.1%) in complex mixtures provides increased sensitivity over 
standard DNA sequencing.(105,107) Moreover, it leads to lower error bias and can be used 
directly on patient samples. It can be applied to low levels of degraded DNA, which is often 
the case with clinical samples. This approach could lead to early detection and monitoring 




of antibiotic resistant subpopulations, which, if left undetected, could lead to selection of 
the resistant population and ultimately, treatment failure.(108-109) 
 
e) Reverse Line Hybridization Assay: The reverse line blot hybridization (RLBH) assay is a 
probe-based method where multiple oligonucleotide probes carrying the mutant sequence 
and wild-type sequence are immobilized on nitrocellulose strips and hybridized with biotin-
labelled PCR products. The membrane can be stripped and reused up to seven times 
without compromising the results. A study by Ajban et al. showed sensitivities for detection 
of resistance to FQs and second-line aminoglycosides to 95.34% and 94.8%, 
respectively.(104) 
The RLBH assay has a turnaround time of three days when performed directly from a 
smear-positive clinical specimen. Compared to PCR-based sequencing and DNA 
microarray techniques, RLBH can be performed without expensive devices.(104)  However, 
the RLBH assay is time-consuming and technically complex, limiting its usefulness in the 
point-of-care setting. 
 
2.4.3 Quality control and standardization of methods for the genetic and 
 phenotypic tests 
 
In 2007, the WHO issued policy guidance on the use of liquid TB culture, DST and rapid 
species identification in low-resource settings.(110) The WHO policy recommends phased 
implementation of these systems as part of a country-specific, comprehensive plan for 
laboratory capacity strengthening and addresses key issues including biosafety, customer 
support, staff training, maintenance of infrastructure and equipment, specimen transport and 
the reporting of results. The WHO has established a structured, systematic process to rapidly 
review the evidence base for new TB diagnostics, ensuring that new tools meet the required 
performance standards. All laboratories should be accredited by a recognized 
national/international accrediting organization and should participate in internal and external 
quality assurance/quality control activities in conjunction with a reference laboratory. These 
programs will assess the reproducibility and the inter-laboratory variability of the methods used 
and adherence to standardized testing procedures.(110) All laboratories should have a 
document control system in operation that will detect and correct significant clerical or analytic 









Table 2: Comparison of different detection methods for XDR-TB 



















Turnaround-time  8 days 28days or 
42days 
10-14 6-8 hours 2 days 1-2hrs 3 days 
Sensitivity 
(Fluoroquinolones) 
90%     90.2%  100% C22% 
(EMB low) 








Yes Yes Yes 
Training Extensive Moderate Moderate Moderate Moderate Moderate Moderate 














Yes No No Yes No No No 
Biohazard risk High High Less High Less Less Less 
Source: C Olga Ignatyeva, Irina Kontsevaya, Alexander Kovalyov, Yanina Balabanova, Vladislav Nikolayevskyy, Kadri Toit, Anda 
Dragan, Daniela Maxim, Svetlana Mironova, Tiina Kummik, Ionela Muntean, Ekaterina Koshkarova and Francis Drobniewskiaff. 
Detection of Resistance to Second-Line Antituberculosis Drugs by Use of the Genotype MTBDRsl Assay: a Multicenter Evaluation 
and Feasibility Study, J. Clin. Microbiol. May 2012. 50(5):1593-1597(46)  
 
2.5  IMPLEMENTATION OF NEW MOLECULAR TB DIAGNOSTIC TESTS FOR 
 SECOND-LINE DRUG SUSCEPTIBILITY TESTING: CLINIC AND LAB 
 READINESS  
 
The implementation of rapid new TB diagnostic techniques is resource-demanding and 
difficult. Many of the tools becoming available require sophisticated, expensive laboratory 
biosafety infrastructure that must be established before these tools can be used. One of the 
challenges that must be addressed before the implementation of a new test is to determine 
how quality assurance will be provided. The South African policy recommends that all 
laboratories that perform drug susceptibility testing (DST) have internal quality assurance 
measures in place and participate in external proficiency testing programmes.(111) In this 
section, we discuss implementation and lessons learnt, specifically focusing on lab readiness 
and clinic challenges. 
 
2.5.1 Technical Complexity 
 
While it may be easy to perform the test, it is often more challenging for trainees to become 
proficient in properly reading the molecular results and interpreting the results correctly for the 
clinicians. There is cross-resistance between the second-line injectables and the assay does 




not allow for specific resistance to individual second-line injectables to be determined. 
Additionally, confusion with LPA often arises if a wild-type band is missing but a corresponding 
mutation band is not present. The disappearance of a wild-type band and the mutant band in 
the same gene may indicate a mixed population which makes results difficult to interpret. 
Within these mixed populations, M. avium is the most common and clinically relevant non-
tuberculous mycobacteria (NTM) species, especially among HIV-infected persons. One can 
either repeat this test or perform speciation tests to exclude the possibility of contamination 
with NTMs. Recently, LPAs have been developed for detection and identification of NTMs and 
these are now commercially available. However, rapid speciation facilities, either on-site or 
through a local reference laboratory, are not readily available in many resource-limited 
settings.(112)   
 
However, phenotypic methods also have their own challenges. A complex internal control 
system has to be established to ensure drug efficiency, that the proper concentration of the 
drug is used and the quality of the media itself. In general, standardization of these techniques 
is difficult, because the efficiency of the drugs alters in different media and with different 
methods. (113) Other general laboratory requirements for implementation of a new diagnostic 
test for TB are summarized in Table 3. 
 
2.5.2 Operational and logistical issues 
 
Some molecular techniques have complex requirements, and therefore it is important to 
clearly map the processes involved in specimen collection and transportation from clinics, 
delivery of specimens to the laboratory and reporting results back to the clinic. Staff training 
in safety procedures and quality control should be considered before beginning 
implementation. Training at management levels, retention of trained personnel, enhancement 
of quality-assurance systems, enhancement of results-reporting mechanisms and supply 
procurement are some of the laboratory aspects that should be considered. In general, 
laboratories need to ensure sustainable systems for long-term provision of instrument 












Table 3: Laboratory requirements for the implementation of new TB diagnostic test 
Activities Comments 
Cooperation and coordination between 
facilities - 
Long term contract with the supplier  To ensure uninterrupted supply of stock 
Proper infrastructure  To ensure uninterrupted electricity supply, availability of equipment  
Technical assistance  To assist troubleshooting related to unusual results and contamination 
Cost of products  - 
 
 
2.6. ALGORITHM FOR IMPLEMENTATION OF DRUG SUSCEPTIBILITY 
 TECHNIQUES FOR SECOND-LINE DRUGS IN A HIGH TB BURDEN 
 COUNTRY  
 
Algorithms should be designed to use existing laboratory services so that specimens can be 
referred to the appropriate level for tests that are not available at the peripheral level 
laboratories. Such referrals are particularly important when patients are suspected of having 
drug-resistant TB, HIV associated TB, when the patients are children or when they have 
extrapulmonary disease. Several rapid methods (114) have been introduced to detect XDR-TB, 
but in spite of all these developments there is still a need to confirm the DST results for XDR-
TB using a liquid based conventional method. Of note is LPA which is limited in the number of 
loci examined and the lack of capacity to differentiate silent mutations from those that effect 
drug efficacy, leading to false positive results. (115) Although sequencing M. tuberculosis from 
sputum from suspected XDR-TB patients suggests it has a role in the management of TB,(116) 
data analysis remains a bottleneck, requiring specialist expertise not readily available in 
clinical laboratories. Thus, to obtain the best performance of laboratory tests it is very 
important to link techniques that complement each other in an algorithm for detection of XDR-
TB. South African policy guidelines recommend GeneXpert (GXP) and LPA for early triaging 
and treatment initiation for patients with DR-TB. Second-line DST of strains, identified as 
RR/MDR-TB using GXP, is also recommended in order to diagnose or rule out XDR-TB. In 
specific instances (i.e. when screening contacts of known XDR-TB patients), a second-line 
DST should be requested together with first-line DST.  
 
Below is the proposed algorithm for detecting patients that are at risk of XDR-TB for example 
treatment failure or default, HIV-infected cases or contacts of drug-resistant cases using a 
combination of molecular techniques with rapid potential for detection of XDR-TB patients that 




may be missed by MGIT 960. In order to rapidly detect second-line drug resistance, the 
Genotype MTBDRsl assay and pyrosequencing have been proposed in this algorithm.(100) 
Pyrosequencing is based on the quantitative detection of released pyrophosphate during DNA 
synthesis,(92)  while the Genotype MTBDRsl v2.0 assay simultaneously detects resistance 
aminoglycosides/cyclic peptides and fluoroquinolones through detection of mutations in the 
relevant genes.(11)   
 
Below is the proposed algorithm for detecting patients that are at risk of XDR-TB for example 
treatment failure or default, HIV-infected cases or contacts of drug-resistant cases using a 
combination of molecular techniques with rapid potential for detection of XDR-TB patients that 
may be missed by MGIT 960. In order to rapidly detect second-line drug resistance, the 
Genotype MTBDRsl assay and pyrosequencing have been proposed in this algorithm 
 




Figure 1: A proposed algorithm to link the molecular line probe assay with solid culture-  












Early and accurate diagnosis of drug resistance in TB is important so that effective treatment 
is provided as soon as possible to ensure rapid cure. To initiate effective treatment, it is 
important to rapidly obtain the results of DST for second-line drugs and put a stop to the 
transmission of drug-resistant TB.  
 
The high mortality rate and risk of nosocomial transmission of XDR-TB have stimulated 
intensive interest in the development and use of rapid DSTs.(117) Significant progress has been 
made in the development of rapid and accurate detection of drug-resistant TB, most notably 
molecular based methods. These technologies have brought great improvement in the 
detection and drug susceptibility testing of drug-resistant M.tuberculosis and have 
enhanced the identification of the disease in HIV-positive individuals. However, it is important 
to realize that their diagnostic performance vary greatly in terms of turnaround time, cost and 
complexity.  Other factors to be considered are appropriateness to the setting, including initial 
and recurrent costs and sustainability.  
 
Case detection of DR-TB in SA has increased to 218 231(1) following a nationwide roll-out of 
Xpert MTB/RIF in 2011. However, this may have limited impact on on-going transmission of 
the disease unless the majority of cases are rapidly initiated on effective treatment. Second-
line DST for AMK and OFX is carried out routinely for all RIF-resistant samples using culture 
and Genotype MTBDRsl. The disadvantage of this is that culture results only become available 
four weeks after initiation of MDR treatment and should be actively followed up, as detection 
of further resistance represents XDR or pre-XDR-TB and necessitates modification of 
treatment. (118). Concerns over the sensitivity of the Genotype MTBDRs/ v1, particularly for 
resistance to the injectables, have delayed implementation in the routine diagnostic algorithm 
due to the fact that it is more sensitive to smear positive sputum and cultivated samples. To 
address this limitation, the Genotype MTBDRsl second version is now available. It is more 
sensitive and can therefore also be performed using smear-negative pulmonary samples. 
 
Discordance between GXP, LPA and/or phenotypic test results is not uncommon, and may 
cause confusion and delay treatment initiation. This highlights the importance of sending a 
second sample for confirmation of positive GXP results, and ideally a third sample to be taken 
at treatment initiation for culture and DST to provide further confirmation in cases of initial 
discordance. In patients with discordant results, correlation with clinical findings is also crucial 
and specialist consultation is necessary to ensure that patients receive the most appropriate 




treatment without adversely affecting their chance of cure, but simultaneously limiting 
exposure to unnecessary and toxic drugs.(118) 
 
Table 3 shows that most rapid methods require adequate laboratories that developing 
countries do not have access to. In practice, more than one method is needed because 
phenotypic methods do not satisfy the requirement of rapid results and genotyping is a better 
alternative for rapid detection of XDR-TB. We therefore recommend use of rapid molecular 
methods for example PSQ for DST of XDR-TB. 
 
The accuracy of sequencing by PSQ is comparable to that of Sanger sequencing, and the 
availability of sequence information enables users to study the association of drug MICs with 
each mutation which makes it a useful tool for predicting the level of drug resistance. (67) In a 
study conducted by Catanzaro, PSQ produced more interpretable results than Genotype 
MTBDRsl for DST against the second-line drugs AMK, KAN, and CAP. (108) This strategy may 
decrease the infectious period, reduce treatment failure and may decrease defaults while 
reducing costs. (72) Despite the simplicity, low cost and relative rapidity of pyrosequencing, the 
methodology requires intensive staff training and more expensive equipment. However, for 
correct management of XDR-TB patients, results still have to be confirmed by a phenotypical 
culture-based method, given the limited number of mutations evaluated by current genotypic 
tests and incomplete understanding of the mechanisms of resistance to second-line drugs. 
 
On that basis, PSQ should be considered as a supplemental method for rapid detection of 
XDR-TB.  Its ability to can detect all known and unknown mutations may help guide treatment 
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PROVINCIAL DIFFERENCES IN TREATMENT OUTCOMES OF 
MULTIDRUG RESISTANT TUBERCULOSIS PATIENTS UNDER 
DOTS-PLUS PROGRAMME: A RETROSPECTIVE COHORT STUDY 




Background: DOTS strategy was implemented in South Africa in 1996. However, the number 
of TB cases continued to rise. Expansion of the DOTS strategy in SA followed rapidly in the 
following years and by the end of 2003; there was complete coverage in all nine provinces. 
The importance of addressing drug resistant TB was further amplified by more recent reports 
on totally drug-resistant tuberculosis. 
 
Objectives: To evaluate MDR treatment outcomes in two different provinces (Eastern Cape 
(EC) and North West (NW) province) for the period 2000-2004 and also identify risk factors 
associated with unfavourable treatment outcomes of MDR-TB.   
Methods: This study included all laboratory confirmed MDR-TB patients from two rural 
provinces chosen on the basis of their different socioeconomic circumstances and provincial 
TB programs. 
 
Results: The treatment success rate of tuberculosis patients on MDR-TB treatment was low 
(40%). A higher number of female than male MDR-TB cases were observed (330 vs 225 
cases, respectively) in these two provinces. Treatment success was strongly influenced by 
the setting where the patients were treated. The EC province had the lowest (13.4%) cure rate 
and the highest default rate of 38.3%. Mortality was significantly associated with HIV-
coinfection in both provinces. 
 
Conclusions: The absence of routine second-line drug susceptibility testing and the 
treatment of MDR-TB with substandard treatment regimen could have led to suboptimal 
diagnosis and poor treatment outcomes. This shows how regional differences in executing 
the TB Control Programme can adversely affect treatment outcomes, and therefore need 








3.2  INTRODUCTION 
 
The World Health Organisation (WHO) reported an estimated 130 000 TB cases in 1995 in 
South Africa (SA) representing one of the highest annual TB incidences (311 per 100 000 
population) in the world. (1) The TB incidence did however vary dramatically by both 
geographical region and population group. South Africa adopted the Directly Observed Short-
Course (DOTS) strategy in 1996 after tuberculosis (TB) was declared a national emergency 
by the WHO, with the aim of improving the TB cure rate to at least 80% and improving the TB 
microscopy services. However, the number of TB cases continued to rise.(2) Expansion of the 
DOTS strategy in SA followed rapidly in the following years and by the end of 2003, there was 
complete coverage in all nine provinces.  
 
Recognising that multidrug-resistant tuberculosis (MDR-TB) poses a considerable risk to 
public health, the WHO and partners launched "DOTS-Plus for MDR-TB" to manage MDR-
TB in 1999.(3) MDR-TB is defined as a specific form of TB that is resistant to  two most effective 
first-line anti-tuberculosis drugs and accounted for at least 480 000 incident cases and 210 
000 attributed deaths globally in 2013.(4) In 2000, the SA National TB Control Programme 
(TBCP) implemented the DOTS-Plus programmes which included a standardised approach 
to MDR-TB management through dedicated provincial MDR-TB centres. Despite the 
implementation of this strategy, SA still has the highest burden of morbidity and mortality due 
to TB, partly due to human immunodeficiency virus (HIV) co-infection. In SA, as many as 70% 
of patients with TB are co-infected with HIV.(5) It is estimated that of all cases of HIV associated 
TB that occur worldwide annually, 30% are in SA.(6) 
 
The prevalence of extensively drug-resistant (XDR) TB, which is MDR with additional 
resistance to both quinolones and second-line injectable agents,(4) is also on the rise. The 
highest rates of MDR and XDR-TB in the country were noted for the Western Cape, Eastern 
Cape and KwaZulu-Natal provinces with treatment success rates below 50% for MDR-TB and 
considerably poorer outcomes for XDR-TB.(7) 
 
There are also a significant number of patients dying with undetected TB.(9) A post-mortem 
study conducted in one hospital in KwaZulu-Natal (KZN) showed that TB rates are much 
higher than estimated.(8) Furthermore and even more alarming, was the observation that of 
those patients who were not receiving TB treatment, 42% were culture positive.(9) In 2013, 26 
023 laboratory-confirmed RR-TB cases were reported in South Africa with only 10 663 (41%) 
reported to have been initiated on second-line anti-tuberculosis treatment.(10)  
 




Statistics from KZN, WC and EC show that they have the highest burden of DR-TB cases in 
South Africa. For example, the number of MDR-TB cases diagnosed in KZN, EC and WC in 
2014 was 6 630, 2 205 and 2 072 respectively(10) and the number of XDR-TB cases diagnosed 
were 147, 240 and 175 respectively.(11) In 2000, the treatment of patients with MDR-TB with 
standardized second-line regimens became a national policy and was implemented through 
the creation of a network of dedicated provincial MDR-TB referral centres.(12) Despite the 
implementation of dedicated referral centres and a standardised MDR-TB treatment regimen, 
the number of laboratory-confirmed cases of MDR-TB in South Africa increased from 2,000 
cases in 2005 to 7 350 cases in 2007.(13)  
 
The importance of addressing drug resistant TB was further amplified by more recent reports 
on totally drug-resistant tuberculosis.(14) Previous reports of MDR-TB have shown poor 
outcomes in HIV-positive patients, with significant mortality in the first few weeks after 
initiation. Other identified risk factors for unfavourable treatment outcomes include alcohol 
abuse, treatment interruption and being male.(14-17) In a report by the MRC, rapid time to 
treatment initiation of MDR-TB treatment in EC had no significant effect on the treatment 
outcomes(18) which meant there could be other risk factors.  
 
In this study we aimed to evaluate MDR treatment outcomes in two different provinces 
(Eastern Cape (EC) and North West (NW) province) for the period 2000-2004 and also identify 
risk factors associated with unfavourable treatment outcomes of MDR-TB.   
 
3.3  MATERIALS AND METHODS 
 
3.3.1  Study setting 
 
This study included all laboratory confirmed MDR-TB patients from two rural provinces chosen 
on the basis of their differences in socioeconomic circumstances, epidemiologic profile TB and 
provincial TB programs (see Figure 2 for the location of both provinces). The Eastern Cape is 
the second largest province in the country with a population of approximately 6.9 million people 
and is characterized by poor socioeconomic conditions. (18)) As of 2013, 755 610 individuals 
were living with HIV in the Eastern Cape Province. (19) In contrast, the North West province is 
a third smallest province with a population size of 3.7 million (19) and is a centre of mining 
activity. The North West had nearly half a million (496,000) HIV positive in 2014.(20) The 
number of MDR-TB cases diagnosed in EC and NW in 2010 was 1782 and 158 respectively 
and the number of XDR-TB cases 320 and 14 respectively.(21) 
 




During the study period, the standardised approach to DOTS-Plus in SA comprised of 
treatment at dedicated MDR-TB referral facilities/centres. MDR-TB referral centres were 
regarded as centres of expertise and therefore were responsible for treatment of MDR 
tuberculosis patients, even after discharge. Second-line drugs were only available through 
these centres, but the bed numbers were limited. Some patients would wait as long as six 
months to get a bed to initiate treatment. Time from diagnosis to treatment initiation of more 
than 180 days was common in MDR-TB patients from EC. Patients were admitted for at least 
the first four months of therapy or preferably until sputum conversion, defined as two 
consecutive negative cultures, at least 30 days apart. Before patient discharge, arrangements 
were made with designated clinics to ensure adherence monitoring and to obtain regular 
feedback on patient progress. In addition, MDR-TB drugs were supplied to the designated 
clinics referral hospitals treating MDR-TB on a patient name basis. Time from diagnosis 
(defined as date of the positive culture result at the initial outpatient evaluation) to treatment 
initiation was recorded. Patients were put on ambulatory treatment after discharge, provided 
that directly observed treatment was ensured. Final treatment outcomes were recorded at the 
referral hospital. Patients were followed-up for two years after treatment completion. Six-
monthly visits were required to assess symptoms and signs of recurrence. 
  





Figure 2: Map of South Africa showing the location of the North West and Eastern Cape  




         
















3.3.2  Study population 
 
Patients were diagnosed with MDR-TB at primary health care facilities. Adult men and women, 
aged 18 years and older, who were referred for treatment at a participating MDR-TB treatment 
centre between 2000 and 2004, with culture confirmed MDR-TB, were eligible for enrolment 
in the study. Since 2000, most of the MDR-TB treatment centres in South Africa have been 
using standardised programmatic management of MDR-TB (DOTS-Plus).(22) Standardised 
therapy was initiated after obtaining drug susceptibility test results.  
 
 
Six district municipalities of the 
Eastern Cape Province 
Five district municipalities of the North West 
Province 




3.3.3  Treatment regimen 
 
The standardised treatment regimen for MDR-TB consisted of a four-month intensive phase 
in which five drugs (kanamycin, pyrazinamide, ofloxacin, ethionamide and either cycloserine 
or ethambutol) were given daily, followed by a 12-18 month continuation phase in which three 
drugs (ofloxacin, ethionamide and either ethambutol or cycloserine) were given daily. The 
continuation phase could be shortened on the basis of clinical judgement provided that 12 
months of treatment was given after sputum conversion, defined as two consecutive negative 
cultures, at least 30 days apart. Daily doses were administered in accordance with published 
guidelines.(21) Patients were seen at regular intervals during the intensive phase and at least 
monthly during the continuation phase.  
 
3.3.4  Patient cohort 
 
Between 2000 and 2004, 2 079 MDR-TB patients from nine provinces were enrolled in the 
cohort study conducted by the MRC and followed up for two years.(7) Of 2 079 patients, only 
1 676 were eligible for a two-year follow-up, 403 were not eligible for follow up, of these 367 
died and 36 was transferred. During this two year follow-up study, monthly follow-up sputum 
samples were collected, cultured (three to nine cultures were collected from each patient) and 
stored for future analysis.  
All enrolled subjects had 1) no previous history of treatment for MDR-TB (i.e. no history of 
treatment with second-line drugs) and 2) had demographic and clinical data (HIV, weight, 
chest X-ray results, TB history etc.) available in an electronic database. Patients with terminal 
illnesses were not included in the study. Patients with extra-pulmonary TB were also excluded 
because they are less likely to have a culture positive sputum sample for the required 
laboratory tests. 
Following provincial policies, HIV counselling and testing were performed where feasible on 
all patients at the start and completion of MDR-TB treatment, and at the completion of the 24 
month follow-up period.  
 
3.3.5  Data collection 
 
Data verification was conducted by the research team which reviewed the charts for all 
treatment failures and a 10% sample of all other clinical records for accuracy of clinical 
outcome data (death, failure, default, transferred, treatment completed, cured). Discrepancies 
were rare, but were resolved through discussion and consensus with the final decision made 
by the coordinating investigator if necessary. 
 






3.3.6  Data Management and Analysis 
 
The standard WHO definitions for treatment outcome in MDR-TB were used. The outcome 
was categorized as favourable in cases of cure and if treatment was completed, and as 
unfavourable in cases of failure, death and default. Classification of treatment outcomes was 
based on smear and culture evaluation, treating clinicians identified the outcome by marking 
the corresponding category on the medical record form. Data on DST to first-line drugs -SIRE 
(site of disease, date of processing sputum, date sputum received, adverse effects, treatment 
start date, treatment end date and treatment outcome) was electronically captured on Epidata. 
Patients who were classified as having been transferred out of the program were excluded in 
the analysis as they did not have monthly sputum culture data.  
 
Demographic and clinical treatment characteristics were analysed and differences between 
the two provinces were assessed separately by province using the chi-square test. To 
determine the risk factors for unfavourable outcomes, a univariate logistic regression analysis 
was conducted in the pooled data from both provinces. Table 4 presents the descriptive 
statistics for the variables used in the study. Variables which had a P value of <0.05 in 
univariate analysis were then included in a multivariate logistic regression analysis. Adequacy 
of the final model was assessed by the Pearson goodness-of-fit test. Kaplan-Meier analysis 
was used to determine risk factors associated with outcomes in time-to-event-based analyses. 
Survival was calculated from date of diagnosis of MDR-TB to the date of death. Data were 
analysed using STATA version 11.0 for Windows (STATA Corporation, College Station, 
Texas). To examine multivariate factors associated with death, a risks regression was 
conducted to compute cause-specific relative hazards using the Cox proportional hazards 
model. 
 
3.3.7  Ethical Statement 
 
Ethical approval to conduct the study was obtained from the ethics committee of the South 
African Medical Research Committee and the Provincial Ethics Committee in each province. 
  
  





3.4  RESULTS 
 
3.4.1  Comparison of clinical characteristics 
  
Of the 1 676 patients that were eligible for a two-year follow up in the cohort between 2000 
and 2004, 556 were patients from the EC (381) and NW (175) province and were included in 
the study. Of 556 MDR-TB patients studied, 329 (59.2%) were women and 226 (40.6%) were 
men. The median age was 37 years (ranging from 18 to 75 years). More than 70% of patients 
in both provinces were classified with bilateral cavitary disease. Overall, >90% had been 
treated for drug sensitive TB previously and approximately 40% were HIV-positive. Patients 
enrolled in both provinces differed in terms of their baseline characteristics; these included 
gender distribution, culture and smear positivity, BMI distribution, cavitary status and HIV 
status (Table 4). 
  
EC had more male MDR-TB patients (46.2%) compared to NW, and were more likely to have 
bilateral disease (Table 4). Time from diagnosis to treatment initiation of more than 180 days 
was common in MDR-TB patients from NW (91.9%) compared to the patients from EC (71.6%) 
(Table 4). Other differences seen were that patients from NW were more likely to be HIV 
positive (46.0% vs. 39.5%) and underweight (73.3% vs. 72.0%), however these differences 
were not statistically significant. 
 
3.4.2  Treatment outcomes 
 
Overall, 223 (40%) of 556 patients had favourable treatment outcomes at the end of therapy, 
157 (28.2%) defaulted, 131 (23.6%) were classified as treatment failures and 36 (6.5%) died 
during treatment (Table 5). Of the 131 patients who defaulted, 44 (33.6%) died within the first 
three months of starting treatment and were more likely to have presented late for treatment 
with a median of 40 days to start MDR-TB treatment after diagnosis. 
 
In the Eastern Cape province, a favourable outcome was achieved in 101/381 (26.5%) cases, 
consisting of those cured 51/381 (13.4%) and treatment completed 50/381 (13.1%). 
Unfavourable outcomes consisted of treatment failure (5.35%), default (38.3%) and death 
(28.9%). In the North West province a favourable outcome was achieved in 122/175 (69.7%) 
cases, consisting of those cured (46.9%) and treatment completed (22.9%). Unfavourable 
outcomes included treatment failure (9.1%), and default (6.3%) and death (12.0%). Nine 
patients transferred out; 2.8% from the North West and 1.1% from the Eastern Cape province. 




The difference between treatment outcomes of the two provinces was statistically significant 
with a P- value of less than 0.05. 
 
Table 4:  Clinical and Demographic characteristics of MDR-TB patients from the Eastern 










 P- value 
Gender      
                  Female 













Age          
                  <50 
                  ≥50 












                 Negative 











   
0.000 
Smear 
         Negative 











               ≤20kg/m2   (Underweight) 















HIV Status             
                  Negative 

















TB history  
                  No 
                  Yes   















                  Bilateral 
                  Unilateral  













Time to treatment 
                  >180 days 













* Patients were diagnosed with MDR-TB at primary health care facilities. Upon treatment initiation, another sputum specimen for 
culture was collected, sent to SAMRC laboratory but some were culture negative. 
 




Table 5: Treatment outcomes in the study cohort of 556 MDR-TB patients by province 
 
 
3.4.3  Risk factors 
 
Risk factors associated with unfavourable outcomes on univiariate analysis were HIV 
coinfection [OR-1.68; 95% CI 1.15-2.45], time to treatment of less than 180 days [OR-26.1; CI 
9.44-72.1], age less than 50 years [OR-2.00; CI 1.18-3.58] and Eastern Cape province [OR 
6.68; CI 4.41-10.1] (Table 6). The only risk factor that was protective against poor outcomes 
was being female [OR-0.64]. When we adjusted for these factors in the multivariate analysis, 
we found that HIV infection, being female and in the EC province were the only significant risk 
factors of unfavourable outcomes, although with wide confidence estimates (Table 6).  
 
The probability of surviving for 19 months (600 days) was 60% in the EC and 69% in the NW 
province (Fig 3). The survival rate among HIV-ve patients at 20 months of treatment in both 
provinces was higher than HIV+ve patients (Fig 4). The overall survival rates in this study were 
found to be 55% and 93% in EC and NW, respectively. A lower survival rate was observed in 
males from the EC as compared to NW. In this study, surprisingly, patients who started 
treatment >180 days after diagnosis had better survival (Fig 5). The survival rate at the end of 
continuation phase (24 months/730 days) in patients less than 50 years of age was 40% and 
was 80% in patients of more than 50 years of age (Fig 6).  
 
In the multivariate analysis, patients with HIV infection and bilateral disease remained the only 
significant risk factors of unsuccessful outcomes in the EC (Table 6). After stratifying on 
Province, those patients in the EC that had bilateral disease and were HIV positive were those 
with worse treatment outcomes, potentially reflecting sicker patients in that Province (Table 7; 







n (%) Overall 
Cured 51 (13.4) 82 (46.9) 133 (23.9) 
Completed 50 (13.1) 40 (22.9) 90 (16.2) 
Died 20 (28.9) 16 (12.0) 36 (6.5) 
Defaulted 146 (38.3) 11 (6.3) 157 (28.2) 
Failure 110 (5.35) 21 (9.1) 131 (23.6) 
Transferred out 4 (1.1) 5 (2.8) 9 (1.6) 
TOTAL 381 175 556 




4.32)], time to treatment: less than 180 days [hazard ratio = 110.10 (27.8-435.10)] and being 
underweight [hazard ratio = 1.90 (0.97-3.75)] stayed associated with poor treatment outcomes 
in addition to being from the Eastern Cape. 
 
Table 6: Univariate and multivariate analysis of demographic and clinical characteristics  
 on unfavourable outcome, EC and NW province, 2000-2004 (n=556) 



































































Table 7:  Multivariable analysis of demographic and clinical characteristics on  
  unfavourable outcome by province, EC and NW province, 2000-2004 (n=556) 
*Bold text shows identified variables with significant p-values less than 0.05 
 
Table 8: Hazard ratio for risk factors for treatment outcomes       
* Bold text shows identified variables with significant p-values less than 0.05      














Age ≤50yrs 1.14 0.79 0.45-2.87 0.38 0.15 0.10- 2.88                  
Bilateral Disease on CXR 3.43 0.01 1.46-5.87  0.59 0.24 0.24-1.41 
HIV +ve  2.77 0.00 1.44-5.35 1.33 0.47 0.61- 2.88 
Variable Hazard ratio p-value 
95% Conf. 
Interval 
HIV +ve  2.45 0.00 1.39-4.32 
Bilateral Disease on CXR 0.73 0.43 0.34-1.59 
BMI (underweight = <20kg/m2) 1.90 0.06 0.97-3.75 
Gender (Female) 0.74 0.28 0.42-1.28 
Age ≤50  0.73 0.46 0.33-1.66 
Time to treatment (<180 days) 110.10 0.00 27.8-435.10 
Prov (EC) 3.37 0.00 1.88-7.40 
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Figure 5: Time to death during MDR-TB treatment by time to treatment after MDR diagnosis (a) >2 years (b) <200 day  
   
 a) Kaplan-Meier survival estimates by time to treatment 
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3.5  DISCUSSION 
 
Only 223/556 (40%) of patients who started standardized MDR treatment had favourable 
outcomes in this cohort originating from two rural provinces in SA. Treatment success was 
strongly influenced by the setting where the patients were treated. Default and death 
accounted for 58.1% of all unfavourable outcomes.  
 
The EC province had the lower (13.4%) cure rate and the higher default rate of 38.3%. The 
low cure rate may be due to poor drug compliance caused by adverse drug effects during 
treatment such as vomiting, nausea, constipation, joint pain etc. Unfortunately, adverse drug 
effects and comorbidities were not properly reported or recorded on patient files. Besides 
adverse drug effects, high death rate (28.9%) and also patients who perhaps defaulted for 
lack of money for transportation to the MDR centres and discontinuing treatment after feeling 
a bit better could have contributed in the low cure rate that was observed in the province. The 
poor outcomes in patients with multidrug-resistant tuberculosis could also have been due to 
highly resistant strains already circulating in the EC. (15)  
 
Age has been identified as an important risk factor for death in tuberculosis patients. In this 
study, an age of less than 50 years was significantly associated with unfavourable outcomes 
in univariate analysis.  However, this association was no longer significant after adjusting for 
other factors, including HIV status. Patients less than 50 years are a sexually active group, 
41% of patients in this group were HIV positive. However, in other studies, higher death rates 
have been noted in the elderly patients.(24-25) The observation of a high proportion of HIV 
positive patients from NW than EC (46.0% vs. 39.5%) is supported by data from a national 
HIV prevalence study in 2002 among MDR-TB patients in the two provinces which revealed 
an HIV prevalence of 66.0%- 30.5% in NW and EC respectively.(28)   
 
Findings from this study are comparable with the proportion of successfully treated patients 
reported in other Green Light Committee (GLC) supported DOTS-Plus projects.(21) A higher 
number of female than male MDR-TB cases were observed (330 vs. 225 cases, respectively) 
in these two provinces, which supports earlier data from a surveillance study conducted in 
South Africa in 2002 of a total of 81 794 TB patients with known sex (95% of all patients) and 
showed that female TB cases had a 1.2 times higher odds ratio of harbouring MDR-TB strains 
than male TB cases.(27) 
 
Mortality was associated significantly with HIV-coinfection in both provinces. The presence of 
bilateral disease was a significant risk factor only in the NW province. A proportion of 




confirmed MDR-TB patients continued with the same first line regimen at their centres while 
waiting for hospitals beds. Antiretrovirals (ARVs) were only available towards the end of the 
study in both provinces, 2004 in EC and 2003 in NW. In the EC, patients that were HIV positive 
were transferred to different hospitals or clinics from the MDR centre where they were treated 
for MDR-TB but were not accredited for ARVs at the time. In the NW province the cure rate 
was 46.9% and the default rate was 6.3%. The better success rate in NW could be attributed 
to differences in provincial TB control programs. Patients in the NW province had a better 
transport system which was arranged from the referral clinics to the MDR centres for their 
follow-up check-ups. 
 
The limitations of the study included firstly, being a retrospective analysis. Secondly, the CD4 
count was not routinely recorded by clinicians in both provinces making this data unavailable 
for analysis and limiting our description of the cohort in relation to severity of HIV infection and 
treatment outcomes. Our current finding of 39.5% (EC) and 46.0% (NW) may underrepresent 
the HIV positive population and may suggest that those patients with an HIV unknown status 
were early in their HIV disease and therefore more clinically similar to HIV negative MDR-TB 
patients. Inclusion of time to treatment in survival analysis may have resulted in bias as 
patients included in the study may be a survival cohort.  
 
The study revealed a consistent association between HIV co-infection and being younger as 
the most important risk factor for poor outcomes. Sixty patients started treatment after >180 
days but did not show a poor outcome compared to patients who received timely treatment. 
potentially reflecting a survival cohort effect in that those who survived that long had a better 
chance of surviving overall. These results could also have been influenced by continuing with 
a first line treatment regimen while waiting for a bed. Further research should evaluate the 
clinical characteristics of patients who were started on MDR-TB start treatment immediately 
after diagnosis in these two provinces. It is likely that patients who benefited from early 
treatment could be the patients that appeared very ill. 
 
The treatment success rate of tuberculosis patients on MDR-TB treatment was low 
(40%).  The key factors to successfully combat this epidemic include earlier diagnosis of MDR-
TB, earlier initiation of appropriate second-line TB treatment, and more aggressive HIV testing 
and ART initiation. The absence of routine second-line drug susceptibility testing and the 
treatment of MDR-TB with substandard treatment regimen could have led to suboptimal 
diagnosis and treatment outcomes. To improve treatment outcome of tuberculosis patients in 
the two provinces, we recommend earlier diagnosis, rapid detection of MDR-TB, initiation, 
management and monitoring of MDR-TB treatment close to their homes at community health 




facilities (CHCs) and PHCs in order to reduce waiting time before patients start treatment. This 
will address transport issues which make it difficult to access treatment sites and patients will 
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DETECTION OF SECOND-LINE DRUG RESISTANCE IN MDR-TB 





Background: Rapid identification of drug resistance and initiation of appropriate treatment is 
key in order to break the chain of transmission in the communities. The availability of rapid 
molecular tests for the detection of extensively drug-resistant TB (XDR-TB) is critical in areas 
with high rates of multidrug-resistant TB (MDR-TB) and XDR-TB. 
 
Objectives: To retrospectively determine resistance patterns against second line drugs 
among newly diagnosed MDR-TB patients in the North West (NW) and Eastern Cape (EC) 
province and how they have acquired resistance during treatment. 
 
Methods: The cultures used in this study were collected from two prospective observational 
studies 1) the DOTS-Plus study and 2) Preserving the Effective TB Treatment Study (PETTS). 
A total of 306 (206 EC and 100 NW) serial isolates from MDR-TB patients with both initial and 
last isolates available were examined. Drug resistance to second line drugs was detected by 
GenoType MTBDRsl assay (version 1) and direct sequencing. 
 
Results: Sequencing confirmed that 10 patients had baseline isolates that were ofloxacin 
sensitive but acquired resistance during treatment. In this study, mutation D94G was the 
frequently observed mutation [37.0% (27/73)], followed by D94Y [19.2% (14/73)], D94H 
[15.1% (11/73)], D94A [9.6% (7/73)] and A90V [5.5% (4/73)]. A total of 2/298 (0.7%) of isolates 
analyzed were detected as heteroresistant. We observed 21% acquisition of resistance to 
second line drugs during treatment. 
 
Conclusions: The accuracy of the GenoType MTBDRsl assay for the detection of FLQ was 
comparable to that of sequencing. However, the test was less accurate for the detection of 
aminoglycosides/CAP.  To overcome this, we recommend MTBDRsl v2.0 which is more 
sensitive than MTBDRsl v1 and is able to detect most common mutations involved in 
resistance to flouroquinolones and aminoglycosides/CAP. There is evidence of acquisition of 
resistance to second line drugs during treatment. 
  




4.2  INTRODUCTION 
 
Efficient tuberculosis (TB) control is based on early diagnosis, followed by rapid identification 
of drug resistance and initiation of appropriate treatment in order to break the chain of 
transmission in the communities. Notable advances in TB diagnostics have been made in 
recent years with the development of new tools for the detection and rapid identification of 
patients with multidrug-resistant tuberculosis (MDR-TB) caused by M. tuberculosis (MTB) 
strains that are resistant to isoniazid (INH) and rifampicin (RIF) and extensively drug resistant 
tuberculosis (XDR-TB) which is defined as MDR-TB with additional resistance to any 
fluoroquinolone (FLQ) and to at least one of three injectable second-line drugs, (kanamycin 
(KAN), amikacin (AMK), and/or capreomycin (CAP).(1)  
 
Globally, an estimated 480 000 people developed MDR-TB in 2014 and an estimated 190 
000 died from MDR-TB. According to the World Health Organization (WHO) 2015 Report, 
XDR-TB had been reported by 105 countries. On average, 9.7% of people with MDR-TB have 
XDR-TB. Levels and trends of drug resistance to second-line drug resistance vary by country 
with resistance to at least one second line drug ranging, from 33% in Thailand to 62% in 
Latvia. Resistance to second-line injectable drugs ranges from 2% in the Philippines to 47% 
in Latvia, while fluoroquinolone resistance prevalence ranges from 7% in the Philippines to 
32% in South Korea.(2) Countries with higher poverty rates tend to have a higher burden of 
drug resistance due to lack of resources and access to the most up to date treatments.  
 
Routine drug susceptibility testing (DST) for all TB patients prior to starting their TB treatment 
would be ideal for monitoring the amplification of resistance and also to ensure that the most 
appropriate treatment is determined. However, because of lack of access to routine DST 
services in most countries, inconsistent diagnoses frequently lead to inadequate treatment, 
increased mortality and inaccurate determination of the true burden of the disease. In 2013, 
the WHO published a report of the Expert Group Meeting (held on 21st March, 2012) that was 
held to review the evidence on Genotype MTBDRsl (Hain Lifescience Nehren, Germany) for 
policy recommendation.(3) It approved the use of line probe assays for MDR-TB diagnosis, 
but not as a complete replacement for conventional culture and DST, and has yet to 
recommend the use of molecular diagnostics for XDR-TB.(3)  
In South Africa (SA) second-line DST for amikacin and ofloxacin is carried out routinely since 
2014, for all RIF-resistant samples using phenotypic culture-based methods to determine the 
growth of MTB bacilli in the presence of individual drugs. These results only become available 
weeks or months following initiation of MDR treatment and should be actively followed up as 
detection of further resistance represents XDR or pre-XDR-TB and necessitates modification 




of treatment. The GenoType MTBDRs/ version 1 rapidly detects mutations conferring 
resistance to second-line drugs (specifically fluoroquinolones, ethambutol (EMB) and the 
injectable agents). The probes contained in the assay do not detect all mutations in these 
genes but are targeted to the most commonly occurring mutations. Fluoroquinolone resistant 
isolates are reported to carry mutations in the quinolone resistance-determining region 
(QRDR) of the gyrA gene,(4) and that a small number have mutations in the gyrB gene(5-6) It 
was previously postulated that efflux pump mechanisms account for FQ resistance in isolates 
with wild-type gyrAB genes.(7) Resistance to second-line injectable drugs is detected by 
targeting the commonly known 1401 and 1484 mutations in the rrs gene(8) and ethambutol 
(EMB) by targeting the emb 306 mutation in the emb gene.(9) 
 
Evaluation of the performance of this test suggested that the sensitivity for detecting 
fluoroquinolone resistance is between 75.6% and 90.6%, and the sensitivity for detecting 
kanamycin resistance is between 77% and 100%.(10-11) In contrast, the sensitivity for detecting 
ethambutol resistance is only 64.2%.(11) This low sensitivity of the test, particularly for 
resistance to the injectables, has delayed implementation in the routine diagnostic algorithm 
and the test is undergoing further evaluation. This assay has diminished accuracy in smear-
negative specimens,(12) meaning that culture isolates still need to be awaited to rule-in 
resistance. Conventional culture and phenotypic DST capacity is still needed to detect XDR-
TB.(13) 
 
To improve the overall performance of Genotype MTBDRsl, and in particular its sensitivity for 
KAN resistance, a new version of the assay (i.e. Genotype MTBDRsl v2.0) has recently been 
developed. Genotype MTBDRsl v2.0 includes two new target genetic regions: the eis 
promoter region −10 to −14 (in addition to rrs) and the gyrB quinolone resistance-determining 
region (QRDR) (in addition to gyrA) for the detection of mutations at codons 536 to 541. The 
target region for EMB (embB) has been removed. Genotype MTBDRsl v2.0 thus includes a 
total of 27 probes for the detection of resistance exclusively to second-line drugs.  
 
Automated liquid cultures systems have significantly reduced the turnaround times for drug 
susceptibility testing (DST) compared to use of solid media. However, it takes more than 10 
days for the detection of drug resistance using automated liquid cultures systems. For 
example, the BACTEC MGIT 960 and BACTEC 460TB need 13.3 days and 10.6 days on 
average to report the drug resistance results, respectively.(14)  Liquid systems are also more 
prone to contamination potentially resulting in misdiagnosis and consequently to a patient 
receiving an incorrect treatment regimen.(15-16) Furthermore, identification of M. tuberculosis 
in liquid systems is greatly affected by loss of mycobacterium viability on long-term storage 




of samples. A rapid, reliable and accurate test is therefore necessary to avoid clinical 
deterioration, improve patient management and prevent further transmissions.(17)  
 
Genotype MTBDRsl assay (Hain Lifescience GmbH, Nehren, Germany), presents a more 
rapid alternative for diagnosis of XDR-TB. It was developed using PCR-based amplification 
and a reverse blotting assay that employs specific probes linked to nitrocellulose strips to 
detect resistance to second-line drugs and ethambutol.  
 
Susceptibility testing for second-line drugs (fluoroquinolones and injectables) was not 
routinely performed on MDR-TB specimens during the study period unless specially 
requested by the attending clinician. Prevalence of primary drug resistance also serves as an 
epidemiological indicator to assess the success of the TB control programme. The aim of this 
study was to retrospectively determine resistance patterns against second-line drugs among 
newly diagnosed MDR-TB patients in the NW and EC province and how they have acquired 
resistance during treatment. 
 
4.3 STUDY SETTING  
 
MDR-TB isolates were obtained from the SAMRC culture collection. These cultures were 
collected from two prospective observational studies: 1) the DOTS-Plus study and 2) 
Preserving the Effective TB Treatment Study (PETTS) which were conducted in five provinces 
in South Africa. 
 
In both studies, sputum specimens were collected from the patients at the specialised MDR-
TB hospitals and sent to the SAMRC in Pretoria where the specimens were cultured for 
mycobacteria at the start of MDR-TB treatment and thereafter on a monthly basis until the end 
of their MDR-TB treatment episode. Three to nine cultures were collected from each patient. 
 
For the purpose of this study only two provinces (EC and NW) were studied and therefore 306 
(206 EC and 100 NW) serial isolates from patients with both initial and last isolates available 
were examined (Fig 8). The reason for studying these two provinces is that both provinces are 
understudied in terms of molecular genotyping of M. tuberculosis isolates. 
  




4.4  DESIGN 
 
This was a retrospective descriptive, laboratory based study of tuberculosis isolates from the 
new MDR-TB patients who presented for treatment at participating MDR-TB treatment centres 
located in the two provinces (EC and NW) of South Africa between 2000 and 2005. 
 
4.5  SUBJECTS  
 
A total of 306 (206 EC and 100 NW) M.tuberculosis isolates collected from MDR-TB patients 
were included in this study (Fig 7). All enrolled subjects had no previous history of treatment 
for MDR-TB (in other words no history of treatment with second-line drugs exist). Informed 
consent was obtained from each study participant before enrolment in the study. Ethical 
clearance for the collection and use of sputum specimens and usage of patient data followed 
by the informed consent of each study participant was obtained from the MRC Ethics 
committee and Provincial Research Committee in each province. Strict patient confidentiality 
was maintained throughout the entire study.  
 
Figure 7: MDR-M. tuberculosis isolates included in the study 
 
 





4.6   MATERIAL & METHODS 
 
Isolates used in this study were collected from patients clinically and laboratory diagnosed as 
MDR-TB. Detection and characterization of mutations associated with resistance to 
fluoroquinolones (FLQ), aminoglycosides/cyclic peptide (AG/CP), and ethambutol (EMB) in 
the gyrA, rrs and embB genes, respectively, was achieved using Genotype MTBDRsl assay 
(version 1). Targeted DNA sequencing of gyrA and rrs gene was performed to confirm the 
results of Genotype MTBDRsl assay. 
 
4.6.1  DNA Extraction 
 
M. tuberculosis isolates were grown on Lowenstein-Jensen medium slopes at 37°C for three 
to four weeks. DNA from mycobacterial cells was extracted using a boiling technique. Briefly, 
a 1 µl loopful of cells was suspended in 200 µl of TE buffer pH8.0 (10mM Tris-CI, 1mM EDTA) 
and heat-killed by incubation at 95°C for 15-20min. The supernatant containing the extracted 
DNA was collected by centrifugation at 12000 rpm for 7min.  
 
4.6.2  Drug susceptibility testing to second-line drugs 
 
The Genotype MTBDRsl assay was performed according to the instructions provided by the 
manufacturer (Hain Lifescience GmbH, Nehren, Germany).(12) The Genotype MTBDRsl assay 
involves DNA extraction from culture isolates or AFB smear-positive respiratory specimens, 
followed by PCR amplification and reverse hybridization. It provides a visual reading of test 
results on nitrocellulose strips.  
 
The Genotype MTBDRsl strip contains 22 probes, including two amplification and 
hybridization controls to verify the test procedures. Besides an M. tuberculosis specific probe, 
PCR control bands for all targeted regions (gyrA, rrs, and embB) are present. For the detection 
of FLQ resistance, three gyrA wild-type probes (WT1, WT2, and WT3) encompass the region 
of the gene encoding amino acids 85 to 97. Six probes (gyrA MUT1 A90V, gyrA MUT2 S91P, 
gyrA MUT3A D94A, gyrA MUT3B D94N/Y, gyrA MUT3C D94G, gyrA MUT3D D94H) 
specifically target the most common mutations. For the detection of AMK-KAN-CAP 
resistance, two probes cover the wild-type region of rrs, while two others (rrs MUT1 and MUT2) 
are designed to assess nucleotide exchanges A1401G and G1484T. For the detection of EMB 
resistance, embB wild-type probe WT1 targets embB codon 306, while the embB MUT1A and 
MUT1B probes were designed to bind to nucleotide exchanges ATG/ATA (M306I) and 
ATG/GTG (M306V).  





Results for the Genotype MTBDRsl assay are interpreted based on the hybridization 
(presence of sharp visible band) to the respective probes coated onto the strips. A test is valid 
and interpretable when Conjugate Controls (CC), Amplification Control (AC) and M. 
tuberculosis complex (TUB) bands are visible along with gyrA Locus control (LC), rrs LC, emb 
LC. Absence of any one of the bands make the test invalid/indeterminate for the respective 
target. In addition, presence of a wild type sequence along with the corresponding mutant 
probe indicates the sample carrying heteroresistant strain. 
 
For a given isolate, if all of the wild-type (WT) probes showed positive staining and the mutant 
probes produced no staining, the isolate was considered susceptible to the three drugs. In 
contrast, an isolate was considered resistant if at least one WT probe was absent or if any 
mutant probe was present. 
 
4.6.3  DNA Sequencing  
 
Targeted DNA sequencing was used to detect second-line drug resistance and confirm the 
results of Genotype MTBDRsl assay. DNA was extracted using a boiling method as well as 
DNA and flanking sequences (amplification product codons 18 to 132). The sequences of 
samples were then submitted for PCR, clean-up and sequencing using an ABI 3130XL genetic 
analyser at the Central Analytic Facility of Stellenbosch University. The chromatograms were 
analyzed using Chromas software. Mutations conferring ofloxacin resistance were determined 
by DNA sequencing of the quinolone resistance-determining region (QRDR) of the gyrA gene. 
The primers used for PCR amplification of the gyrase gene were: gyrA forward primer 5’–TGA 
CAT CGA GCA GGA GAT GC–3’ and gyrA reverse primer: 5’–GGG CTT CGG TGT ACC TCA 
TC–3’. Mutations conferring to KAN/AMK/CAP resistance were determined by DNA 
sequencing of the region encompassing nucleotide 1401 of the rrs gene (amplification product 
nucleotides 1339 to 1528). The rrs gene (1400-1500 region) was amplified from each isolate 
using primers: rrs290 forward 5’–TGCTAC AATGGCCGGTACAA-3’ and rrs290 reverse 5’-
CTTCCGGTACGGCTACCTTG-3’. We chose to not include the emb gene for sequencing as 
EMB was not considered one of the effective four drugs even though it was included in the 
regimen.  
  





4.7  RESULTS  
 
A total of 306 MDR M.tuberculosis strains isolated from patients with MDR-TB in the EC and 
NW province of South Africa were tested for resistance to the second-line antituberculosis 
drugs AMK/KAN/CAP, OFX and EMB. Readable Genotype MTBDRsl assay results were 
obtained for 298 MDR-TB isolates. Representative DNA patterns obtained with Genotype 
MTBDRsl are shown in Figure 8. Susceptibility pattern results obtained by Genotype MTBDRsl 
are presented in Table 9. 
 
Figure 8: Example of DNA patterns obtained by testing MDR-TB isolates using GenoType 
MTBDRsl (v1.0) assay. The positions of the oligonucleotides and control probes are shown on the right 
side of the strip. From right to left are susceptibility patterns of different isolates;  Lane 1, example of 
isolate OFXr KAN/CAPr EMBr pattern; Lane 2, OFXs KAN/CAPs EMBs; Lane 3, OFXs KAN/CAPs 
EMBs; Lane 4, OFXr KAN/CAPsEMBr, (heteroresistant); Lane 5, OFXr KAN/CAPsEMBr 








Table 9: Resistance of the 298 MDR M. tuberculosis strains to second-line anti-  
 tuberculosis drugs 
DRUG RESISTANCE PATTERN NO OF STRAINS % 
Susceptible to second-line drugs  93 31.0 
OFX only 5 1.7 
AMK/KAN/CAP only 3 1.0 
EMB only 83 27.9 
AMK/KAN/CAP+EMB 44 14.8 
OFX+EMB 19 6.4 
OFX+AMK/KAN/CAP 4 1.3 
OFX+AMK/KAN/CAP+EMB 47 15.8 
OFX=Ofloxacin; KAN=Kanamycin; AMK= Amikacin; CAP=Capreomycin; EMB=Ethambutol 
     
Of all the isolates tested 97.4% (298/306) were found valid to all the three targets 
(gyrA (FQ), rrs (AG/CP) and embB (EMB), respectively) by Genotype MTBDRsl assay, and 
the remaining 2.6% (8/306) were found invalid/indeterminate. Two of 298 isolates had both 
the wild-type, mutant OFX and EMB bands, suggesting heteroresistance.(18-19)  
Heteroresistance is the phenomenon of simultaneous occurrence of drug resistant and drug 
sensitive organisms in the same sample.(4,19)  In all eight isolates with invalid results, the rrs 
gene control band was absent. Similar results were obtained after repeating the assay and 
hence these isolates were excluded from the analysis. The results discussed below are of 
isolates with valid results. 
 
Fluoroquinolone resistance: Table 10 summarizes drug susceptibility patterns of FQ-
resistant and FQ-sensitive isolates with valid results. Of the total 298 isolates analysed, 223 
(75.5 %) showed wild-type patterns in the gyrA gene and the remaining 75 (25%) isolates had 
mutations detected by the Genotype MTBDRsl assay in the gyrA gene. One (1.3%) ofloxacin-
resistant isolate was detected as heteroresistant, indicating the coexistence of mutant and 
wild-type strains.  
 
Among the 75/298 (24.5%) OFX-resistant isolates, the gyrA MUT 3C/D94G was the most 
prevalent mutation occurring in 27/75 (36%) isolates followed by the gyrA MUT 3B band/D94Y 
(14/75; 18.7%), gyrA MUT 3D/D94H (11/75) is a rare mutation which has been detected only 
in silico and hence thought to be undetectable in vitro; 14.7%), gyrA MUT 3A/ D94A (7/75; 
9.3%), and gyrA MUT 1/A90V mutation (4/75; 5.3%) (see Table 10).  
 




In 10 of 75 isolates (13.7%) both gyrA MUT 3C/D94G and gyrA MUT 3B band/D94Y (2/10); 
gyrA MUT 3C/D94G and gyrA MUT 3D/D94H (4/10); gyrA MUT 3A/ D94A and gyrA MUT 
1/A90V (4/10) were present (see Table 10). 
 




Table 10: Genotype MTBDRsl test results for the detection of FLQ, AMK-CAP, and EMB resistance in 298 smear-positive MDR-TB isolates with  
 valid results 
• a = r, resistant; s, susceptible. 
• b = WT, wild-type pattern with all respective bands; ΔWT, lack of hybridization with the indicated wild-type probe (WT1, WT2, or WT3)
Resistance and Genotype MTBDRsl pattern (gyrA, rrs, embB)b 
Resistance and Genotype 
MTBDRsl pattern (gyrA, rrs, embB)a 
 
Gene region of mutations detected Genotype MTBDRsl result : 
(No. (%) of strains) 
FLQ    
    gyrA ΔWT3, MUT 3C FLQr D94G 27 (36) 
    gyrA ΔWT3, MUT 3B FLQr D94N/D94Y 14 (18.7) 
    gyrA WT, MUT 3B  15 (20) 
 
FLQr (heteroresistant) D94N/D94Y 1 (1.3) 
    gyrA ΔWT3, MUT 3D FLQr D94H 11 (14.7) 
    gyrA ΔWT3, MUT 3A FLQr D94A 7 (9.3) 
              gyrA ΔWT1, MUT 1 FLQr A90V 4 (5.3) 
               gyrA ΔWT1,  ΔWT 3, MUT 3A,  MUT 3B,  MUT3C, MUT 3D,         
               gyrA MUT 1 
FLQr D94A, D94N/D94Y,  D94G, D94H, A90V 10 (13.3) 
              gyrA ΔWT3 FLQr D94X 1 (1.3) 
      gyrA WT  FLQs None 223 (75.5) 
    
AMK-KAN-CAP    
    rrs ΔWT1, MUT1 AMK/KAN/CAPr A1401G 70 (23,5) 
    rrs ΔWT2, MUT2 AMK/KAN/CAP r G1484T 20 (6.7) 
    rrs ΔWT1,  ΔWT2 AMK/KAN/CAP r - 8 (2.7) 
       rrs WT AMK/KAN/CAPs None 200 (67.1) 
    
EMB    
    embB ΔWT1, MUT1A EMBr M306I 118 (61.4) 
    embB ΔWT1, MUT1B EMBr M306V 56 (18.8) 
               embB WT1,  MUT1A,  MUT1B EMBr (heteroresistant) M306I, M306V 1 (1.3) 
               embB ΔWT1, MUT1A,  MUT1B EMBr M306I, M306V 7 (2.3) 
       embB ΔWT1,  ΔWT2 EMBr - 10 (3.4) 
               embB WT EMBs None 106 (35.6) 
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Aminoglycosides/cyclic peptide resistance: Table 10 summarizes drug susceptibility 
patterns of AMK/KAN/CAP-resistant and AMK/KAN/CAP-sensitive isolates with valid results. 
Of 298 isolates with valid results, 98 (32.8%) had mutations in the rrs gene (see Table 9). 
Forty eight isolates had acquired resistance to ethambutol. Of the 98 AMK/KAN/CAP resistant 
isolates, the rrs MUT 1/A1401G was the most prevalent mutation occurring in 70/98 (71.4%) 
isolates. The remaining 20/98 (20.4%) had rrs MUT 2/A1484T mutation which has been 
previously been reported in South Africa by Said et al.(20) while 8/98 (8.2%) were resistant by 
absence of wild-type bands at positions 1401 and 1402 (WT1) and position 1484 (WT2) in the 
rrs gene with no developing mutations band. 
  
Ethambutol resistance:  Table 10 summarizes drug susceptibility patterns of EMB-resistant 
and EMB-sensitive isolates included in the study. Of 192/298 (64.4%) ethambutol resistant 
isolates 118 (61.5%) had mutations in the embB MUT 1A/M3061. The second most prevalent 
mutation of the 192 EMB resistant isolates was embB MUT 1B/M306V (56/192; 29.1%), 
followed by isolates with both embB MUT 1A/M3061 and embB MUT 1B/M306V (8/192; 4.2%) 
of which one was heteroresistant. The remaining isolates (10/192; 5.2%) were resistant by 
absence of wild-type patterns with no developing mutations band.  
 
The 298 isolates with valid results included two isolates that were not paired, in other words 
only the baseline or final isolate was available. One hundred and forty eight (148) patients had 
DST results for both the baseline and final TB culture positive isolate available. In 50 of 148 
patients (34.0%) the DST pattern of the last available isolate was different from that of the 
patient's initial isolate. Of these, 31 (70.0%) patients had last available isolates that became 
resistant to an additional drug indicating that the infecting strain gained a mutation conferring 
resistance during treatment. Eighteen patients had last available isolates that had lost 
resistance, in other words the final isolate became sensitive after initially being resistant to 
one or more of the drugs tested. One patient had a final available isolate that had both gained 
and lost resistance in one of the drugs. Table 11 shows the number of reversions for each of 
the second-line drugs tested. 
 
Sequencing for detection of Ofloxacin and Kanamycin resistance: Our panel included 
104 isolates that were further tested by DNA sequencing to confirm the results of the Genotype 
MTBDRsl. A total of 34/104 (32.7%) and 15/104 (14.4%) isolates were available for sequence 
analysis associated with mutations in gyrA and rrs gene respectively, thus 70/104 (67.3%) 
could not be included because of a bad sequence data either due to an insufficient 
or poor quality template. Since ethambutol is not considered an active drug in MDR-TB, we 




did not sequence the embB gene for ethambutol resistance in this study, although it was added 
to the MDR-TB regimen during the period of the study.




Table 11: QRDR mutations identified in patients whose initial and last isolates (34) had different DST profile 
 
*For each patient, the first row is the results of the initial isolate; whereas second row are results of the final isolate 
 
*Patient 
DST pattern by Hain 
assay 
No. of months between the initial and final isolates Mutations in gyrA by Direct Sequencing 
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Analysis of gyrA gene for mutations in Ofloxacin resistant isolates: Comparison between 
the Genotype MTBDRsl assay and the DNA sequencing results of the gyrA gene showed 
discordant results in 6/34 (17.6%) isolates. Of these, four of the 34 isolates resistant by 
Genotype MTBDRsl assay showed wild-type sequence, while two isolates that were sensitive 
by GenoType MDRTBsl assay were resistant by sequencing method. The remaining 28 
isolates (82.4%) were correctly identified as OFX resistant by Genotype MTBDRsl assay.  
 
The 28 fluoroquinolone-resistant as identified by DNA sequencing displayed various mutations 
in the GyrA QRDR, corresponding either to mutations frequently reported in the literature 
(mutations in codons 90 and 94) or more rarely encountered mutations (codons 88 and 80) 
(Table 11). 
 
Analysis of rrs gene for mutations in Kanamycin resistant isolates: Fifteen isolates were 
available for analysis of mutations in the rrs gene. Analysis of the DNA sequencing 
chromatograms confirmed the presence of an A1401G mutation in the rrs gene in 10/15 (67%) 
patient isolates (not shown). Of these, five of isolates identified as susceptible by Genotype 
MTBDRsl assay had a mutation by sequencing method.  
 
4.8  DISCUSSION  
 
Currently, there are different molecular tests that identify MDR and XDR M. tuberculosis and 
these are mainly DNA sequencing and line probe assays. The Genotype MTBDRsl assay is a 
rapid line probe assay for the detection of resistance to fluoroquinolones, ethambutol and 
aminoglycocydes in M. tuberculosis. In the present study, we assessed the capacity of the 
Genotype MTBDRsl test to detect mutations linked to resistance to OFX, AMK/KAN/CAP and 
ethambutol and compared them to mutations on genes conferring resistance to OFX and KAN 
as detected by sequencing.  
 
 
This retrospective study showed a high prevalence (68.8%) of resistance to second-line drugs 
for MDR-TB and that of XDR-TB (51/298; 17.1%) as detected by Genotype MTBDRsl.  The 
overall rate for reporting a valid test was 97.4% (298/306) and the rate for indeterminate result 
was 2.6% (8/306). Resistance to all drugs (including ethambutol) tested was 15.8% (47/298) 
and resistance to both OFX and KAN was 4 (298)1.3%. These findings confirm the high rates 
reported by Tracy Dalton and colleagues in South Africa that resistance to any second-line 
drugs was 44.7% and XDR-TB was 10.6%.(21) 
 




A total of 6/34 (17.6%) isolates showed discrepancies of results in the gyrA gene between the 
Genotype MTBDRsl and sequencing. Four of the 34 isolates resistant by Genotype MTBDRsl 
assay showed widtype pattern by sequencing, while two isolates that were sensitive by 
Genotype MDRTBsl were resistant by sequencing. Among the gyrA targeted mutants in the 
Genotype MTBDRsl assay D94G was the frequently observed mutation [37.0% (27/73)], 
followed by D94Y [19.2% (14/73)], D94H [15.1% (11/73)], D94A [9.6% (7/73)] and A90V [5.5% 
(4/73)]. Isolates with the D94Y (19.2%) mutation had both the gyrA WT3 deletion + MUT3B 
hybridization and gyrA WT3 + MUT3B hybridization using the Genotype MTBDRsl test as 
observed, as described by Kiet et al.(11) 
 
Furthermore, (2/298) 0.7% isolates analysed were detected as heteroresistant. The 
heteroresistance was in association to gyrA and embB gene, whereas previous studies have 
reported heteroresistance mostly in relation to rrs gene.(11) Heteroresistance might also result 
from specific treatment regimens, host fitness, differently mutated strains or hypermutable 
alleles of the DNA repair genes.(4,22) High rates of heteroresistance to FLQ-resistant isolates 
have been reported before in Germany (21.9%),(16) Russia (16.6%),(4) and Vietnam (21.4%);(20) 
however, the rates were low in our study (7.9%) and in France (4.2%).(23) 
 
The concordance between Genotype MTBDRsl and sequencing was 82% for all gyrA gene 
and 67% for the rrs gene. Sequencing confirmed that 10 patients had baseline isolates that 
were ofloxacin sensitive but acquired resistance during treatment. These patients never 
received flouroquinolone therapy for TB prior to the initiation of this study. Exposure to OFX 
and other FQ for the treatment of other bacterial diseases could have contributed to acquiring 
resistance or they were infected with a MDRTB strain already resistant to FQ ie pre-XDR-TB 
.(24-25) This finding  is  concerning because it results in a poor treatment outcome for example 
early relapse and also because resistance to one fluoroquinolone often means cross 
resistance to others.(26) There are also reports of OFX-resistant strains of M. tuberculosis or 
the developing of OFX resistance during treatment.(27) This has been attributed to use of 
fluoroquinolones in patients who have unsuspected tuberculosis. There are reports of the 
acquisition of fluoroquinolone resistance by Mtb after as little as 23 and 13 days of 
fluoroquinolone treatment.(28-29) On that basis, the rapid diagnosis of TB drug resistance is 
recommended to avoid the spread of resistance to second-line drugs. 
 
Mutation in A1401G is related to high level resistance to second-line aminoglycosides.(30-31) In 
this study, A1401G [71.4% (70/98)] mutation was observed using Genotype MTBDRsl assay, 
followed by A1484T [20.4% (20/98)]. Eight of 98 (8.2%) were resistant by absence of wild-




type bands with no developing mutation bands which could be due to silent mutations in this 
region, which do not result in an amino acid exchange.  
 
The study had certain limitations. The resistance rate for fluoroquinolones and injectable drugs 
may have been underestimated because of the unavailability of phenotypic testing. The 
absence of sequencing data due to poor DNA yield on a certain proportion of samples with 
follow up isolates means that we could have underestimated resistance to second-line drugs 
that develops overtime during treatment. When using the boiling technique to isolate DNA, 
proteins are not removed in samples and this could have inhibited the sequencing reaction. 
The other reason for the poor DNA yield is likely the long storage time of the culture samples 
on solid media. 
 
The accuracy of the GenoType MTBDRsl assay for the detection of FLQ was comparable to 
that of sequencing. However, the test was less accurate for the detection of 
aminoglycosides/CAP. To overcome this we recommend MTBDRsl v2.0 which is more 
sensitive than MTBDRsl v1 and is able to detect most common mutations involved in 
resistance to flouroquinolones and aminoglycosides/CAP. There is evidence of acquisition of 
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EMERGENCE OF ADDITIONAL DRUG RESISTANCE DURING 
STANDARDIZED MDR-TB TREATMENT 
5.1 ABSTRACT 
 
Background: In order to address the increasing incidence of MDR-TB, the South African 
National TB Program recommended the implementation of to a standardized treatment 
regimen in 2000, consisting of 4-month intensive phase with 5 drugs pyrazinamide, 
ethambutol, ethionamide, ofloxacin, and either amikacin or kanamycin followed by a 12- to 18-
month continuation phase without AMK/KAN. This policy advocated that MDR-TB treatment 
should be conducted in hospital settings until culture conversion.  
 
Objective: To assess the impact of implementing a standardized MDR-TB treatment regimen 
in two South African provinces, the Eastern Cape (EC) and North West (NW) by 
retrospectively quantifying the acquisition of drug resistance to second-line drugs in serial 
cultures. 
 
Methods: A total of 556 MDR-TB patients from the Eastern Cape and North West provinces 
were enrolled in the study. We investigated whether DST pattern, HIV infection status, and 
treatment outcomes were associated with the acquisition of drug resistance. Spoligotyping 
was used to compare the genotypes of the MDR-TB isolates obtained at the time of treatment 
initiation with last available isolate. 
 
Results: Seventy-five percent (n=106) of patients included in the study had poor treatment 
outcomes (died, defaulted, failed treatment). Of 556 MDR-TB patients, 106 (64 females and 
42 males) had DST and spoligotyping results. Of these 48 had an initial and last available 
isolate, and of these 22 (45.8%) had genetic DST results that differed. In 11/22 (50%) patients 
the spoligotype patterns changed suggesting reinfection. In 9/22 (41%) of these patients the 
reinfecting strain had a resistance profile that showed additional resistance relative to the initial 
isolate (amplification of resistance). In 23 of the 26 (88.5%) remaining patients, the spoligotype 
pattern of these serial isolates remained constant, suggesting persistent disease. The Beijing 
and Latin American Mediterranean (LAM) families were found to be more frequent in 48 MDR-
TB patients studied, with 29/48 (60.4%) and 7/48 (14.6%) respectively. Out of 29 patients with 
strains belonging to Beijing family, 24/29 (82.8%) had unfouvarable outcomes.  
 




There was no statistically significant difference in the amplification of resistance between 
patients who were HIV positive and those who were HIV negative (p-value = 0.250). 
Acquisition of OFX resistance was more common in patients with poor treatment outcomes 
(failed defaulted or died) compared to patients with good treatment outcomes (cured, 
completed treatment) (54% vs. 13%, p-value =0.03879).  
 
Conclusions: Amplification of resistance to second line drugs was observed in 45.8% of 
MDR-TB patients. This implies that the implementation of standardized MDR-TB treatment in 
the absence of knowledge of the degree of resistance in circulating MDR-TB strains increases 
the risk of amplification of resistance during treatment. Furthermore, institutionalized MDR-TB 
treatment increases the risk of nosocomial reinfection with strains that are more resistant than 
the initial infecting strains. 
 
5.2  INTRODUCTION 
 
The first multidrug resistant-tuberculosis (MDR-TB) case, defined as resistance to isoniazid 
(INH) and rifampicin (RIF), was diagnosed in South Africa in mid-1980s. (1) A drug resistance 
survey in the Western Cape Province conducted by the South African Medical Research 
Council (SA MRC) from July 1992 to May 1993, found 1.1% of new and 4% of retreatment TB 
patients had MDR-TB.(2) Subsequent to this, another survey was conducted in Mpumalanga 
Province, showing 2% MDR-TB among new patients and 8% among patients previously 
treated for TB.(3) In 2001 the National Drug Resistance Survey, performed by the SAMRC and 
sponsored by the World Health Organization (WHO), was conducted to estimate the burden 
of drug resistant TB in all nine South African provinces. The survey found that 1.6% of newly 
diagnosed and 6.6% of previously treated TB patients had MDR-TB. Drug resistance among 
newly treated cases for INH, RIF, ethambutol (EMB) and streptomycin (SM) were 2.6%, 0.2%, 
0.0% and 1.8% respectively. In addition, the survey reported that resistance to EMB was rare.  
Resistance to pyrazinamide (PZA) and second-line drugs were not tested.(4) One-fourth of all 
MDR-TB isolates were found to be resistant to all four first-line drugs against which they were 
tested, but second line drug (SLD)susceptibility testing was not performed, so estimates of the 
percentage of extensively drug resistant tuberculosis (XDR-TB) isolates are not available. 
 
In response to these findings, in 2002 the South African National TB Program recommended 
changes to treatment guidelines, from an individualized to a standardized treatment regimen 
for MDR-TB as proposed by the WHO.(5) This included a four- to six-month hospital-based 
intensive phase treatment consisting of PZA, EMB, ethionamide (ETH), ofloxacin (OFX) and 




either amikacin (AMK) or kanamycin (KAN) followed by a 12- to 18-month outpatient 
continuation of the regimen omitting the injectable (AMK or KAN). The continuation phase 
could be shortened on the basis of clinical judgement provided that 12 months of treatment 
was given after sputum conversion (negative culture). Hospital-based intensive phase 
treatment was recommended to ensure adherence and to monitor for adverse events. On 
discharge, patients received clinic-based care with directly observed therapy-short course 
(DOTS) workers monitoring treatment adherence at home. Susceptibility testing for second-
line drugs (fluoroquinolones and injectables) was not routinely performed on MDR-TB 
specimens unless specially requested by the attending clinician. These tests were done by 
the National TB Reference Laboratory or the National Health Laboratory Services (NHLS). 
Thus, in the majority of cases, second-line drug sensitivity testing (SLDST) results were not 
known at treatment initiation. Accordingly, sputum culture conversion from positive to negative 
for MDR-TB was the most important indicator of efficacy of treatment. 
 
The impact of implementing a standardized MDR-TB therapy policy in South Africa on 
treatment outcomes and acquisition of additional drug resistance has not been widely 
evaluated. Numerous reports also suggest that by not testing for additional first- or second-
line resistance prior to treatment initiation, and hence not adjusting therapy, increased the risk 
of the developing additional drug resistance.(5-6)   
 
To measure the genetic relationship between different M. tuberculosis strains the 
spoligotyping technique was used and the results were correlated with drug-susceptibility test 
results and treatment outcomes. In this study we aimed to assess the impact of implementing 
a standardized MDR-TB treatment regimen in two South African provinces, the Eastern Cape 
(EC) and North West (NW) by; 1) retrospectively quantifying the acquired drug resistance to 
second-line drugs in serial cultures; 2) assessing treatment outcomes and sputum culture 
conversion; 3) differentiating persistent disease from reinfection. We investigated whether the 
implementation of this policy significantly contributed to the emergence of extensively drug-
resistant tuberculosis (XDR-TB), defined as MDR-TB plus resistance to a fluoroquinolone and 
a second-line injectable, in individual patients.(7) 
 
5.3  MATERIAL AND METHODS  
 
5.3.1  Study population and isolates 
 
For this study, we retrospectively analysed results of patients prospectively enrolled in the 
study titled “DOTS-Plus for MDR-TB in South Africa: Systematic Evaluation of Standardized 




Treatment Regimen Applied Under Tuberculosis Control Program Conditions” conducted by 
the SAMRC between July 2000 and December 2004. A total of 1066 MDR-TB patients were 
enrolled to investigate the clinical and cost effectiveness of the standardised MDR-TB 
treatment regimen under the TB control programme conditions in South Africa. To meet the 
inclusion criteria, patients were 18 years and older with confirmed MDR-TB presenting at 
MDR-TB referral centres in the nine provinces and regarded as eligible for standardised MDR-
TB treatment according to the National Tuberculosis Programme (NTP) policy. Patients were 
excluded if they had a previous history of treatment for MDR-TB (i.e. received second-line 
drugs). 
 
From this cohort, we selected all patients from the Eastern Cape and North West Provinces, 
in order to compare the effect of implementation of this standardized MDR-TB treatment 
regimen in two different provincial settings. To monitor treatment response, monthly serial 
samples were sent to the MRC Supranational Reference Laboratory for mycobacterial culture 
and INH and RIF DST using BACTEC 460 radiometric method. All cultures were subsequently 
stored at 70C on Löwenstein–Jensen (L-J) medium and BACTEC vials for future studies. We 
included in the analysis culture-positive patients in whom both the initial and final available 
isolates were available. The initial isolate is defined as the first available isolate for a patient 
and the final isolate is defined as the last available isolate for the same patient. Ethical 
approval for the study was received from the MRC and the respective provinces.  
 
5.3.2 Sample processing, DNA isolation, and second-line drug susceptibility 
 testing 
 
Patients were diagnosed with MDR-TB at primary health care facilities. As part of routine 
diagnosis, sputum samples were processed by the NHLS. Upon treatment initiation, sputum 
specimens were sent to the MRC laboratory in Pretoria where they were cultured for 
mycobacteria and thereafter on a monthly basis until the end of their MDR-TB treatment 
episode. The first sputum specimen received by the MRC from each patient represented an 
initial isolate used in this study. All sputum samples collected from high risk patients (presence 
of TB-HIV co-infection, first-line treatment failure, TB relapse or contact with a MDR-TB strain, 
suspected primary drug resistance) were subjected to culture and DST for INH and RIF using 
the BACTEC 460 radiometric method (Becton Dickinson Diagnostic System, Sparks, MD). As 
a backup, LJ slants were inoculated with 0.1ml processed specimen and incubated at 37°C 
for up to eight weeks or until positive. All positive cultures were stored at 7oC for future use 
and long term storage resulted in loss of viability. 
 




Specimens that were culture positive on both LJ and BACTEC 460 were used for second-line 
drug susceptibility testing using Genotype MTBDRsl assay (Hain Lifescience GmbH, 
Germany). DNA from mycobacterial cells was extracted using a boiling technique by scraping 
one or two scoops of cells from LJ slants. The cells were suspended in 200 µl of TE buffer 
pH8.0 (10 mM Tris-CI, 1 mM EDTA), and heat-killed by incubation at 95°C for 15 to 20 minutes. 
Thereafter, the extract was centrifuged at 12000 rpm for 7 minutes and the supernatant 
containing the extracted DNA was collected by aspiration.  
 
From BACTEC 460 vial, 1.0ml of the culture was removed with a tuberculin needle and syringe 
and placed in a 2.5ml micro-centrifuge tube. The tube was then closed and centrifuged in a 
micro-centrifuge for 15 minutes at 13,000 r.p.ms. After centrifugation the supernatant was 
removed and the sediment re-suspended in 300µl molecular grade water. This suspension 
was then boiled at 96oC in a water bath for 15 minutes to lyse and inactivate the bacilli. After 
boiling, the suspension was then placed in a sonicating water bath for a further 15 minutes. 
5µl of this supernatant was used for the amplification reaction. 
 
Spoligotyping was done according to the internationally standardised protocol to detect the 
presence or absence of 43 variable spacers in the direct repeat region of Mycobacterium 
tuberculosis genome.(8) This genotyping method was used to compare the genotypes of the 
MDR-TB isolates obtained at the time of treatment initiation with the last available isolates. 
Reinfection was defined as an active TB case whose initial and follow-up isolates showed 
significant differences in spoligotype-defined shared type (ST).(9) Persistent disease was 
defined as active TB in a patient whose initial and follow-up isolates had the same ST. 
 
5.3.3 Statistical analysis 
 
The statistical software STATA version 12.0 (StataCorp, USA) was used to analyse the data. 
The data is expressed in numbers and percentages. The χ2 test was used to compare the 
differences between patients included and excluded in the study. P<0.05 was considered to 
indicate a statistically significant difference between two groups. 
 
5.4  RESULTS 
 
Among 1066 MDR-TB patients eligible for the study in nine South African provinces from 2000 
to 2004, 556 (52.2%) were from EC and NW province (Figure 9). Stored cultures were 
available from 350 (62.9%) MDR-TB patients, however, the yield of DNA was insufficient from 
244 (69.7%) of these cultures and were excluded from subsequent analysis. Among the 




remaining 106 MDR-TB patients that had both second-line drug susceptibility testing (SLDST) 
and spoligotyping results, 48 (33 EC, 15 NW) had an initial and last isolate available while 58 




Figure 9: The study selection process  
 
 
Out of 106 patients included in the study, there were 64 female and 42 male patients (Table 
12). The age of patients ranged from 18 years to 65 years. A high proportion of these patients, 
64 (60%) were HIV-positive. Twenty-six percent of patients included in the study had 
















48 MDR-TB patients had initial and last available 
isolates  
 
58 MDR-TB patients had single isolates 
available  
 
EC = 33 (69.0%) patients 
NW = 15 (31.3%) patients  
 
EC = 34 (58.6%) patients  
NW = 24 (41.4%) patients 
 
106 MDR-TB patients had second-line DST and 
spoligotyping results  
244 patients: 2nd line DST and 
spoligotyping not successful due 
to low DNA yield 
556 MDR-TB patients: 333 EC and 223 NW analysed in 
the current study 
 
 1066 MDR-TB patients presenting for TB treatment at 
MDR-TB centers in 9 provinces were eligible for the 
study enrolment between 2000-2004 
  
206 patients had cultures that 
were either contaminated or 
could not be found or LJ slants 
dried up/showed no visible 
growth. 
 
510 patients were from other 
provinces not included in the 
current study 
350 MDR-TB patients set up for second-line DST and 
spoligotyping   




died, and 6.6% failed treatment. Sixty-three percent of patients were from the Eastern Cape 
and 37% from the North West province. 
 
There were no statistically significant differences observed between patients included in the 
study versus those excluded in terms of age (p=0.513), provincial origin (p=0.439), HIV status 
(p=0.889) and treatment outcomes (p=0.239) except for there were more females in the 
excluded population (p=0.031) (Table 12). 
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Treatment outcome: 











Default 32 (30.2) 126 (28.0) 158 (28.4) 
Death 38 (35.9) 119 (26.4.) 157 (28.2) 
Treatment Failure 7 (6.6) 41 (9.1) 48 (8.6) 
Unknown treatment outcomes 2 (1.89) 
 
25 (5.6) 27 (4.9) 
*Conversion category:  
Early-conversion (2-6weeks) 
Mid-conversion (7-18weeks) 



















Baseline smear status: 
Negative 
Positive 








64 (14.2)  
 
230 (41.4) 
252 (45.3)  
74 (13.3) 
0.002 
* Information missing for 27 cases among patients included in the study and 69 cases among patients not included in the study 
 




Genotypic analysis of the isolates from the 48 patients with initial and last available isolates 
showed that 26 (54.2%) patients had an initial isolate with mutations identical to the final 
isolate (Table 13). In 23 of the 26 (88.5%) patients, the spoligotype pattern of these serial 
isolates remained constant, suggesting persistent disease, while in the remaining three 
(11.5%) patients the spoligotype pattern changed during the course of disease, suggesting 
reinfection with a strain with the same resistance conferring mutations (Table 14).  
 




Drug-susceptibility testing showed that 3/26 (6.3%) of these patients had XDR-TB at baseline, 
while 9/26 (34.6%) had pre-XDR-TB. Six out of 26 (15%) patients had resistance to OFX and 
3/26 (12%) had resistance to KAN/CAP. Out of the 26 patients, 19 showed culture conversion 
at three months later while the remaining seven patients did not achieve sputum culture 
conversion (Table 14). Five (67.9%) patients were cured, six (14.3%) died, 10 (17.9%) 
defaulted, 5 (19%) completed treatment and none failed treatment.  
 
Twenty-two (46.0%) of 48 patients who had initial and final isolates had genetic DST results 
that differed (Table 15). Eleven (50.0%) of these 22 patients had an initial isolate with a 
spoligotype pattern that differed from the final, suggesting reinfection while another eleven 
(50%) patients had initial isolates with a spoligotype identical to the final isolate, suggesting 
acquisition of resistance. Taking in account the low discriminatory power of spoligotyping, it is 
likely that some additional reinfection might have been missed. Of the 11 cases where 
reinfection was observed, nine were reinfected with a strain harbouring additional resistance 
conferring mutations, while two were reinfected with a strain harbouring fewer mutations 
(Table 15). A higher proportion of reinfection cases were observed in the Eastern Cape 
province 8/11 (72.7%) than in the North West province 3/11 (27.3%). 
 
The Beijing and Latin American Mediterranean (LAM) families were found to be more frequent 
in 48 MDR-TB patients studied, with 29/48 (60.4%) and 7/48 (14.6%) respectively (Table 14 
&15). Other spoligotypes i.e (LAM), S family, T, X, Haarlem (H), and East- African Indian (EAI) 





Spoligotype Pattern Identical 23 (88.5%) 11 (50.0%) 34 (71.0%) 
Spoligotype Pattern Different 3 (11.5%) 11 (50.0%) 14 (29.0%) 
TOTAL 26 (54.0%) 22 (46.0%) 48 (100%) 




were observed in one or two patients. The Beijing family was more common 21/29 (72%) in 
cases form the Eastern Cape. Beijing genotype was also the predominant genotype among 
patients that had gained resistance 14/22 (63.6%). Of these, 28.6% were reinfected with a 
strain harbouring additional resistance conferring mutations. Out of 29 patients with strains 
belonging to Beijing family, 24/29 (82.8%) had unfavourable outcomes, 13 (44.8%) of patients 
died during TB treatment, 10 (34.5%) defaulted and 1 (3.4%) failed treatment. 
 
The proportion of isolates that developed resistance during treatment ranged from 79.0% for 
OFX, 10.5% for KAN/CAP and 10.5% for EMB (Table 15). Of the 17 patients who gained OFX 
resistance, seven (41.2%) also gained resistance to KAN/CAP or EMB. In 33.3% of isolates, 
resistance to OFX was gained during the intensive phase of treatment (Table 15). 
 




Table 14:  Rate and amplification of drug resistance among 26 MDR-TB patients who did not gain additional resistance i) =Initial isolate   
  ii)=Final isolate
 






Time to gain 
resistance  in 
months 
*Time to Initial 
Culture 
conversion(weeks) 




OFX KAN/CAP EMB 
1075 (i) positive defaulted 9 Never converted 49 EC LAM4 S S R 
         (ii) positive defaulted    EC LAM4 S S R 
1117(i) negative died 1 Never converted 29 EC Beijing R R R 
         (ii) negative died    EC Beijing R R R 
1207 (i) negative cure 2 4 71 EC Beijing S S S 
         (ii) negative cure    EC Indo-Oceanic S S R 
1345 (i) negative died 1 24 33 EC Beijing R R R 
         (ii) negative died    EC Beijing R R R 
1370  (i) positive died 3 Never converted 5 EC Beijing R S R 
         (ii) positive died    EC Beijing R S R 
1455 (i) positive defaulted 6 Never converted 39 EC Beijing R R R 
         (ii) positive defaulted    EC Beijing R R R 
160  (i) positive cure 1 13 70 NW T1 S S R 
        (ii) positive cure    NW T1 S S R 
164 (i) positive died 11 3 13 NW Beijing R S R 
       (ii) positive died    NW Beijing R S R 
1678 (i) positive cure 1 13 71 NW X3 S S S 
         (ii) positive cure    NW X3 S S S 
1724 (i) positive cure 1 unknown 72 NW LAM4 S S S 
         (ii) positive cure    NW LAM4 S S S 
1823 (i) positive completed 10 28 73 EC MANU2 R S R 
         (ii) positive completed    EC LAM4 R S R 
1884 (i) negative defaulted 2 28 73 EC Beijing S S R 
         (ii) negative defaulted    EC Beijing S S R 
2138 (i) negative died 3 unknown unknown EC Beijing S S R 
         (ii) negative died    EC Beijing S S R 
2353 (i) negative defaulted 1 Never converted 17 EC Beijing S S S 
        (ii) negative defaulted    EC Beijing S S S 
2438 (i) negative defaulted 3 13 70 EC X3 S S S 
         (ii) negative defaulted    EC X3 S S S 
2974 (i) positive defaulted 3 unknown 70 EC Beijing S S S 
         (ii) positive defaulted    EC Beijing S S S 
530 (i) negative completed 20 8  70 NW LAM9 S S R 
        (ii) negative completed    NW LAM9 S S R 
568  (i) positive completed 2 10 65 EC Beijing S S S 
        (ii) positive completed    EC Beijing S S S 
621 (i) negative defaulted 9 Never converted 69 EC H3 S R S 
       (ii) negative defaulted    EC Beijing S R S 
643 (i)  positive defaulted 1 9 59 NW Beijing S S S 
       (ii) positive defaulted    NW Beijing S S S 
668 (i) negative cure 9 10 65 EC Beijing S R R 
       (ii) negative cure    EC Beijing S R R 
713  (i) negative defaulted 4 Never converted 91 EC Beijing R S R 
        (ii) negative defaulted    EC Beijing R S R 
742 (i) negative defaulted 1 9 38 NW LAM4 S S S 
       (ii) negative defaulted    NW LAM4 S S S 
990 (i) negative died 
4 11 59 
NW 
Euro-
American S R S 
       (ii) negative died 
   
NW 
Euro-
American S R S 
795(ii) positive completed 3 12 72 NW H1 S S R 
      (ii) positive completed    NW H1 S S R 
793(ii) positive completed 5 24 70 NW LAM11_ZWE S S S 
     (ii) positive completed    NW LAM11_ZWE S S S 
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Table 15: Rate and amplification of drug resistance among 22 MDR-TB patients who gained resistance/sensitivity to second-line drugs during   
Isolate no. Relevant Characteristics Drug resistance pattern Cohort 
- HIV status Treatment outcome Time to gain resistance 
in months 
*Time to Initial Culture 
conversion(weeks) 
Time to Final 
outcome (wks) 
Province Genotype OFX KAN/CAP EMB Persistent/Reinfection 
97    (i) Negative Died 8 Never converted 34 EC Beijing S S R  
       (ii) Negative Died - -  EC Beijing R R R Persistent 1 
113  (i) Not known Died 3  Never converted 56 EC Beijing S S R  
       (ii) Not known Died - -  EC Beijing S R R Persistent 2 
143  (i) Negative Cured 7 19 73 NW H1 S S R  
        (ii) Negative Cured - -  NW H1 S S S Persistent 3 
187  (i) Negative Died 9  Never converted 50 EC Indo-Oceanic S S S  
       (ii) Negative Died - --  EC  Beijing R R R Reinfection A 
352  (i) Negative Completed 3 Not known 71 EC H3 S S S  
        (ii) Negative Completed -   EC H1 R R R Reinfection B 
544  (i) Positive Completed 29 Not known Not known NW X3 S S R  
       (ii) Positive Completed -   NW XE R S R Reinfection C 
717  (i) Negative Died 22 Never converted 92 EC Beijing S R R  
       (ii) Negative Died -   EC Beijing R R R Persistent 4 
756  (i)  Positive Died 6  Never converted 24 EC Beijing S R R  
       (ii) Positive Died - -  EC Beijing R R R Persistent 5 
780  (i) Positive Failure 27  Never converted 144 EC Beijing S S S  
       (ii) Positive Failure - -  EC Beijing R R S Persistent 6 
913  (i) Positive Defaulted 16 Never converted 70 EC S R R R  
        (ii) Positive Defaulted - -  EC LAM3 R R S Reinfection D 
1031 (i) Positive Defaulted 8  Never converted 39 EC Euro-American R R R  
         (ii) Positive Defaulted - -  EC Beijing S S S Reinfection E 
1207 (i) Negative Cured 2 16 71 EC Beijing S S S  
         (ii) Negative Cured -- -  EC Indo-Oceanic S S R Reinfection F 
1971  (i) Positive Died 1 11 62 EC Beijing S S R  
         (ii) Positive Died - -  EC Beijing R S R Persistent 7 
2040  (i) Positive Died 11 54 65 EC LAM3 S S R  
         (ii) Positive Died - -  EC T1 R R R Reinfection G 
2072  (i) Negative Completed 8 24 103 EC Beijing  S S R  
          (ii) Negative Completed  - -  EC X3 R S R Reinfection H 
2371  (i) Negative Defaulted 1 18 69 EC Beijing S R R  
          (ii) Negative Defaulted - -  EC Beijing R S R Persistent 8 
2468  (i) Negative Cured 1 17 70 NW X2 S S S  
         (ii) Negative Cured - -  NW X2 S S R Persistent 9 
788   (i) Not known Not known 13 Not known Not known EC S S R R  
        (ii) Not known Not known - -  EC LAM3 R R R Reinfection I 
809  (i) Negative Died 15 20 30 EC Beijing S R R  
       (ii) Negative Died - -  EC X3 R R R Persistent 10 
864  (i) Positive Died 10 56 72 EC X3 S S R  
       (ii) Positive Died - -  EC X3 R S R Persistent 11 
912  (i) Positive Died 2 1 21 NW LAM4 S S R  
       (ii)  Positive Died - -  NW  Beijing S R R Reinfection J 
975  (i) Positive Defaulted 6 65 65 NW LAM3 S S S  
       (ii) Positive Defaulted - -  NW Beijing R S R Reinfection K 
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The median initial sputum culture conversion time was 19 weeks in patients who gained 
resistance to one or more additional drugs versus 18 weeks among those who did not gain 
resistance (p-value =0.001). Those who did not convert were more likely to die or had 
defaulted treatment for multidrug resistant TB. 
 
We next investigated whether DST pattern, HIV infection status and treatment outcomes were 
associated with the acquisition of drug resistance (Table 15). Six (40.0%) of 15 isolates that 
had gained OFX resistance were from patients that were HIV-negative, whereas nine (60.0%) 
of 15 were from HIV-positive patients. There was no statistically significant difference in the 
amplification of resistance between patients who were HIV positive and those who were HIV 
negative (p-value = 0.250). Amplification of OFX resistance was more common in patients 
with poor treatment outcomes (failed defaulted or died) compared to patients with good 
treatment outcomes (cured, completed treatment) (54% vs. 13%, p-value =0.03879). 
 
5.5  DISCUSSION AND CONCLUSION 
 
In this study, we investigated whether the implementation of an in-hospital and standardized 
MDR-TB treatment regimen contributed to patients gaining additional resistance during 
treatment. We assessed this policy in two South African provinces, the Eastern Cape (EC) 
and the North West (NW), by retrospectively quantifying the extent of additional resistance to 
second-line drugs that was gained during standardized MDR-TB treatment.  
 
Our analysis of 48 MDR-TB patients, with initial and last available isolates, showed that 45.8% 
gained resistance to second-line drugs during treatment. These results are extremely 
concerning as they suggest that these hospitalized patients being treated with a standardized 
MDR-TB treatment regimen were at significant risk of acquiring additional resistance or 
becoming infected with M. tuberculosis strains that had more resistance than their baseline 
infecting strain. Alarmingly, 17% of MDR-TB patients gained resistance to a level of XDR-TB 
during treatment. These findings are in agreement with previous reports which have shown 
that additional resistance gained during treatment increases the risk of poor outcomes 
including death (11-12) and the emergence of XDR-TB. (13) A clear association between 
resistance to OFX and poor treatment outcome in MDR-TB patients have been shown in 
several studies.(14-16) In the current study, resistance to OFX was frequently gained (31.3%) of 
which 10.4% was gained during the intensive phase of treatment.  
 
This study showed that two mechanisms were responsible for resistance to be gained during 
treatment. Firstly, by spoligotyping, we found in 23% of patients the genotypes of the initial 




and final isolates differed significantly, suggesting nosocomial reinfection. This implies that 
patients are susceptible to reinfection during treatment (17) following exposure to strains which 
harbour less or more resistance causing mutations. Using only spoligotyping could have 
underestimated the proportion of reinfection, as showed in the studies performed in the 
Netherlands.(18) To obtain a better estimation of the reinfection proportion, secondary 
genotyping methods such as the IS6110-restriction fragment length polymorphism (IS6110-
RFLP) and mycobacterial interspersed repetitive units-variable number of DNA tandem 
repeats (MIRU VNTR) have been proposed. While the two methods have been highly 
discriminatory, one drawback is a large amount of sample required to obtain sufficient amounts 
of DNA. In this study we could not grow the bacteria as the stored culture was not viable. This 
resulted in low DNA yield as observed during DNA Sequencing. 
 
Reinfection with a strain which has additional mutations can be explained by the fact that the 
reinfecting strains are at a selective advantage when exposed to the standardized treatment 
regimen when compared to the initial strain. However, this does not hold true for situations 
where the reinfection strain has less resistance causing mutations unless there are additional 
mutations which were not tested for in this study. Additionally, this could also reflect the 
difference in the level of fitness between the two strains present in these patients.(19-21) 
 
The fact that nosocomial transmission occurs implies that patients remained infectious despite 
starting the MDR-TB standardized treatment. To stop transmission of MDR-TB, studies have 
shown that patients need to be initiated promptly on effective treatment (22) and greater 
infection control methods need to be implemented. This may be largely overcome with the 
implementation of community based treatment for MDR-TB as is currently recommended by 
the SA-National Tuberculosis Programme (NTP) guidelines. Secondly, this study showed that 
in 22/106 (21%) additional mutations conferring resistance were acquired during treatment 
implying that additional resistance could have developed as a result of treatment with an 
inappropriate regimen for an extended period of time.  
 
We acknowledge that this study has limitations. Only patients with initial and follow up positive 
cultures, not those with one culture available, were included in the study. This study could 
have underestimated or overestimated the proportion of patients with acquired drug resistance 
to second-line drugs even though it is administered to all new patients with MDR-TB. However, 
this is unlikely as the study could not identify any difference between the included and 
excluded group. 
 




Also, we did not investigate all other resistance markers for gaining resistance. As a result of 
the non-viability of cultures for most patients, we used Genotype MTBDRsl assay to detect 
second-line drug resistance. Genotype MTBDRsl assay cannot be used to “rule out” the 
presence of underlying resistant populations which may mean that the frequency of 
amplification of resistance may be higher than estimated. Lastly, the use of spoligotyping, 
which has a lower level of discrimination, may be insufficient to identify reinfection in 
genetically related strains leading to an under-estimate of reinfection. Another limitation of this 
study is that we did not further differentiate Beijing isolates into typical and “atypical” isolates 
and therefore could associate certain genotypes with specific drug resistance patterns.   
 
In conclusion, the high levels of amplification of drug resistance to second-line drugs observed 
in this study generally reflect the implementation of a weak standard regimen and the 
requirement of patients to remain cohorted in hospital for much of the initial treatment. Lack of 
early DST may have resulted in the use of an ineffective treatment regimen, thereby leading 
to acquired drug resistance. In view of the increasing MDR-TB, there is a need for rapid 
comprehensive DST for early detection of drug resistance and strengthened regimens in order 
to provide patients with improved second-line treatment options, improve treatment success 
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CHARACTERISTICS AND TREATMENT OUTCOMES OF PATIENTS 





Background: This retrospective cohort study reports on rates of drug resistance and 
treatment outcomes for MDR-TB patients notified between 2000 and 2004 and examines 
factors associated with death/failure. 
 
Objectives: To describe the clinical characteristics and prevalence of second line drug 
(SLD) resistance among MDR-TB patients in the DOTS-Plus (DP) cohort and its impact on 
clinically defined treatment outcomes. 
 
Methods: This retrospective study included all MDR-TB patients registered in the DP cohort 
between 2001 and 2004. Frequencies and cross-tabulations were used to describe the 
variables and chi square (x2) for associations. Significant variables (<0.001) were entered 
into a logistic regression analysis  
 
Results: Among the 2212 drug resistant patients 2079 were new MDR-TB patients included 
in the analysis. Of the 2079 patients, 1290 (62.0%) were male, and 436 (21.1%) were HIV 
positive.  The treatment success rate was 51.3%, followed by 20.4% default rate, 17.7% 
death rate and 8.9% failure rate. Mortality rate was significantly high (94.8%) among patients 
who have been treated for drug susceptibile TB before compared to new MDR-TB patients 
(5.2%). In the multivariate analysis patients with low weight, resistance to pyrazinamide and 
ofloxacin remained the only statistically significant factors associated with a lower chance of 
having favourable outcomes. Compared with first line drugs, second line drug resistance 
(kanamycin and ofloxacin, cycloserine was higher in patients with unfavourable outcomes. 
Logistic-regression analysis for factors associated with death/failure yielded odds ratios that 
were significant for weight <50kg, resistance to PZA and OFX. 
 
Conclusions: High default (20.4%) and death rate (17.7%) indicate urgent need for early 
identification and referral of patients with the history of treatment of TB, shorter and effective 
regimen in order improve patient outcomes and reduce ongoing MDR-TB transmission within 
the community.  




6.2  INTRODUCTION 
 
In 2014 it was estimated that there were 480 000 of multi drug-resistant tuberculosis (MDR-
TB) cases globally.(1) MDR-TB is defined as tuberculosis strains with resistance towards the 
two most potent anti-tuberculosis drugs, isoniazid and rifampicin. Globally MDR-TB is typified 
by < 50% successful treatment outcomes, and high death rates.(2) South Africa ranks second 
among the highest burden MDR-TB countries,(3) and has been treating MDR-TB patients since 
2000, with equally dismal treatment outcomes.(4-5) In 2005 strains of MDR-TB with resistance 
to two groups of second-line drugs (SLDs): kanamycin (KAN) or amikacin (AMK) and 
ofloxcacin (OFX) were described(6), and termed extensively drug-resistant TB (XDR-TB). At 
that time concerns about the impact of XDR-TB on global TB control targets emerged as 
patients with this form of disease were characterised by exceptionally high death rates. (7)  
 
XDR-TB, as for MDR-TB, is a laboratory diagnosis and requires that Mycobacterium 
tuberculosis (Mtb) to be cultivated from sputa or other clinical specimens, whereupon 
sensitivities against SLDs are done by growing the organisms in presence of the drugs in the 
BACTEC MGIT 960 system. As Mtb grows slowly in vitro, the results of drug susceptibility 
testing (DST) can take up to 12 weeks to be available, during which period the patient may 
deteriorate due to sub-optimal treatment and during which time additional drug resistance can 
be acquired. It is believed that resistance against any of the two classes of SLDs will have an 
adverse impact on treatment outcomes, but the relative contribution of resistance as compared 
to other clinical signs of the patient is unknown. Despite having SLD-DST available, performing 
these assays remain challenging, most important are the difficulties in standardization of the 
methodology. Furthermore, very little is known about the correlation between bacteriologically 
demonstrated drug-resistance, either by phenotypic or genotypic methods,(8) with clinical 
resistance, where clinical resistance is defined as failure or death. Such information would be 
useful not only to estimate the extent of the problem in this high-risk population, but also for 
reviewing the tuberculosis control program and for developing the necessary steps for 
preventing the spread of MDR-TB in the country. The use of SLD-DST to guide individualized 
regimens has been highlighted more recently with reports on patients with drug-resistance to 
all anti-TB drugs(9-10) and the need to be cautionary in defining different classes of SLD 
resistance in the absence of data on the correlation with clinical response to treatment.(2) 
 
In 2000, South Africa implemented standardized programmatic management of MDR-TB in a 
study known as DOTS-Plus (DP).(11) In this protocol, 2079 MDR-TB patients with newly 
culture-confirmed disease, from all nine provinces, were enrolled from 2000-2004. Only 
isoniazid (INH) and rifampicin (RIF) susceptibility were done as background resistance of the 




SLDs AMK/KAN and the fluoroquinolones (OFX) were believed to be low due to limited used 
and availability prior to 2000. It was however recognised that some patients would have 
primary or acquired resistance to SLD, and that these patients may require individualized 
regimens. Therefore, any patient that was still culture-positive at any stage during months 6 
to 9 of treatment was eligible for having SLD susceptibility testing done on a culture, and 
adjustment of regimen, depending on the clinician’s decision.  
 
The aim of this study was to 1) describe the prevalence of SLD resistance among MDR-TB 
patients in the DP cohort 2) its impact on clinically defined treatment outcomes and identify 
risk factors for death and failure.  
 
6.3  MATERIAL & METHODS 
6.3.1  Patient population 
 
New MDR-TB patients were prospectively enrolled from 2000-2004 into the DOTS-Plus (DP) 
cohort (5) for standardized treatment. Full description of the cohort and treatment outcomes 
were as previously described by Farley et al.(5) All nine provinces in the country participated 
in DP, and the provincial MDR-TB hospitals had the option to submit monthly sputum 
specimens to the South African Medical Research Council (SAMRC) for culture and 
biobanking. A SLD treatment regimen was used, consisting of a 4 month hospital-based 
intensive phase of pyrazinamide (PZA), ethambutol (EMB) or cycloserine/terizidone (Cs/Trd) 
(if resistant to ethambutol), ethionamide (ETO), ciprofloxacin/ofloxacin (CFX/OFX), and 
amikacin/kanamycin (AMK/KAN). This was followed by an additional 12 to 18 months, 
outpatient based continuation phase depending on culture conversion, in which the injectable 
agent and PZA were omitted. Susceptibility testing for SLDs was not routinely performed on 
MDR-TB specimens during the study period unless specially requested by the attending 
clinician. Case Report Forms (CRFs) were prospectively completed by a clinician or nurse. 
The patient data collected included demographic data, baseline treatment and clinical 
information, as well as monthly treatment and clinical data. HIV testing was offered to all 
patients upon start of MDR-TB treatment, but antiretroviral (ART) therapy has only been 
available to MDR-TB patients since late 2004. Standardized treatment outcome and culture 
conversion definitions were used.(12) Under DP patient demographic, baseline clinical, 








6.3.2  Bacteriology and Second-line Drug Susceptibility Testing 
 
The MDR-TB provincial hospitals had the option to send monthly sputum specimens to the 
SAMRC TB Laboratory in Pretoria for culturing, biobanking, and SL DST when deemed 
necessary. This however resulted in only selected sputa from patients’ being submitted to 
SAMRC, which limited the applicability of any SLD resistance findings across the cohort. Upon 
receiving sputum specimens at the SAMRC’s laboratory, specimens were cultured in duplicate 
on Lowenstein-Jensen (LJ) slants and stored at 7°C. For patients not converting at months 6-
9, duplicate slants were sent from the SAMRC to the National Health Laboratory Service 
(NHLS) for SLD susceptibility testing on MGIT. Drugs tested were kanamycin (5 mg/l), 
amikacin (4 µg/mL), ofloxacin (2.0 μg/ml), pyrazinamide (100 μg/ml), cycloserine (5 mg/l) and 
ethionamide (5.0 μg/ml).  
 
6.3.3  Data Management 
 
Data were captured in an Epi-Data, and exported to SAS. Frequencies and cross-tabulations 
were used to describe the variables and chi square (x2) for associations. Significant variables 
(<0.001) were entered into a logistic regression analysis  
 
A favourable outcome was defined as a treatment outcome of cure or completed and 
unfavourable outcome a treatment outcome of death, default or failure. Patients who 
transferred out of the MDR Facility and patients who defaulted during treatment were excluded 
from data analysis. 
 
Descriptive analysis: continuous data were summarised using means standard deviances, 
and 95% CI as appropriate. The students’ t-test was used to compare the two groups in 
univariate analysis when the assumption of normality was met, else nonparametric test such 
as the Mann-Whitney rank sum test statistic was used. Categorical variables were tabulated 
and Pearsons chi-square test statistic or Fishers’ exact test statistic was used to test for 
statistical significance. 
 
6.4  ETHICS 
 
The DOTS-Plus study was approved by the Ethics Committee of the South African Medical 
Research Council (SAMRC) and research committees of the nine provinces, and patients 
gave informed consent. It also subsequently received review and approval from the Johns 
Hopkins University Bloomberg School of Public Health Investigational Review Board.  
 




6.5  RESULTS 
 
Baseline characteristics 
Between 2000-2004, a total of 2212 DR-TB patients were enrolled into the DOTS-Plus cohort. 
Among the registered cases, 133 (6.0%) were found to have been previously treated for MDR-
TB. The remaining 2 079 were new MDR-TB cases from all 9 different provinces of South 
Africa. These cases were included in the analysis of this study, see (Figure 1).  
 
 








The cohort of 2079 patients consisted of mostly males (62.0%). The majority (55.7%) of 
patients had bilateral cavity disease and the human immunodeficiency virus (HIV) status was 
known for 60.8%, among which 34.5% of those screened were HIV-positive. Half of the 2079 
patients (1066, 51.3%) were successfully treated, 36 (1.7%) were transferred out, 186 (8.9%) 
failed treatment, the default rate was 424 (20.4%) and 378 (17.7%) of patients died. Table 16 
shows the baseline demographic and clinical characteristics of patients included in the study. 
There were no statistically significant differences observed in terms of gender (p=0.058), age 
(p=0.061), cavitary status (p=0.322) (Table 16). One hundred and seventy nine 9.5%, patients 
had not been treated before for drug susceptible tuberculosis prior to initiation of MDR-TB 
treatment (Table 16). 
 
Drug Resistance Pattern 
At onset of treatment EMB susceptibility was known for 2079 of patients, of which 659 (31.7%) 
were resistant. For 436 (20.9%) of patients phenotypic KAN susceptibility results were known, 
among which 65 (15.0%) were resistant. For 326 (15.7%) of patients OFX susceptibilty 
(phenotypic) were known, among which 47 (14.4%) were resistant. A total of 309 (14.9%) of 
patients in the cohort had susceptibility results for both OFX and KAN, amongst which 30 
(9.7%) met the criteria for XDR-TB. The most common second-line resistance observed was 
ethionamide, followed by KAN, Cs and OFX. 
 




Table 16. Demographics and clinical characteristics of patients, N=2079  

























































         
Age (years)        0.061 














































































         








































         
Cavitary status        0.322 







































HIV status at diagnosis        0.000 
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Factors associated with favourable outcomes 
In the multivariate analysis (see Table 17), patients with a lower weight, resistance to 
pyrazinamide and OFX remained the only statistically significant factors with less chance of 
having favourable outcomes (defined as a treatment outcome of cure or completed).  
 
Table 17. Multivariate analysis of demographic and clinical characteristics on favourable 
outcomes (n=2079) 
 Values highlighted bold are significant risk factors 
 
Risk factors for death or failure 
In a univariate analysis we compared variable cured/completed and died/ failed. Except 
gender and classification of MDR-TB, all other variables included in the study were 
significantly different between completed/cure and death/failure.  
 
In multivariate logistic regression analysis, weight <50kg (OR, 0.38; 95% CI, 0.27-0.53, 
P<0.001), resistance to PZA (OR, 0.14; 95% CI, 0.07-0.31, P<0.001), resistance to OFX (OR, 




Variable Multivariate analysis 
Odds 
ratio 
p-value 95% Conf. Interval 
Weight <50kg 0.58 0.00 0.46-0 .74 
COMORB 0.99 0.99 0.90-1.10 
HIV +ve  1.52 0.04 1.01-1.33 
New MDR, with no previous TB 
treatment 
1.10 0.55 0.81-1.50 
Resistance to ethambutol 1.03 0.64 0.91-1.17 
Resistance to kanamycin 0.80 0.23 0.56-1.15 
Resistance to ethionamide 0.58 0.03 0.36-0.93 
Resistance to pyrazinamide 0.16 0.00 0.08-0.32 
Resistance to ofloxacin 0.56 0.00 0.41-0.75 
Resistance to cycloserine 2.22 0.00 1.37-3.63 




Table 18. Multivariate analysis of factors associated with death/failure  
 
Values highlighted bold are significant risk factors 
 
6.6  DISCUSSION 
 
MDR-TB is more difficult to treat and successful outcome rate is low compared to drug 
susceptible TB. Accurate and rapid diagnosis of MDR-TB is important not only to put patients 
on effective treatment but also importantly to prevent further transmission of resistant strains. 
In addition, understanding the risk factors responsible for unfavourable treatment outcomes 
(defined as death, failure or default) among MDR-TB patients is necessary to improve the 
treatment outcomes. 
 
Half of the 2079 patients (1066, 51.3%) were successfully treated, 36 (1.7%) were transferred 
out, 186 (8.9%) failed treatment, the default rate was 424 (20.4%) and 367(17.7%) of patients 
died. The Eastern Cape province had the highest number (34.4%) of default cases followed 
by the Western Cape province (20.5%); which is in agreement with other studies.(16-17) High 
default rate observed in this study is consistent with previous reports by Farley et. al on 
outcomes of DR-TB patients in eight provinces between 2000 and 2004, and a study by Brust 
et. al among DR-TB patients in KwaZulu-Natal (2000-2003), which both found a 21% default 
rate.(5,18) 
The proportion of isolates with resistance to EMB amongst new patients was 31.7% higher 
than the drug resistance survey conducted in South Africa from 2001 to 2002 (0.8%).(19)  
Although phenotypic DST of M. tuberculosis is considered as the gold standard, liquid culture 
based system, including MGIT 960 system has been reported to yield poor reproducible DST 
Variable Multivariate analysis 
Odds 
ratio 
p-value 95% Conf. 
Interval 
Weight <50kg 0.38 0.00 0.27-0.53 
Gender 0.77 0.21 0.51-1.14 
COMORB 1.09 0.23 0.94-1.27 
HIV +ve  1.16 0.08 0.98-1.36 
Resistance to ethambutol 0.99 0.89 0.84-1.17 
Resistance to kanamycin 0.91 0.67 0.59-1.39 
Resistance to ethionamide 0.47 0.01 0.27-0.82 
Resistance to pyrazinamide 0.14 0.00 0.07- 0.31 
Resistance to ofloxacin 0.58 0.00 0.41-0.83 
Resistance to cycloserine 1.98 0.02 1.12-3.49 




results which may result in some misclassification.(20) This is due to a narrow range between 
the critical breakpoint for EMB resistance and the MIC for susceptible strains.  The low 
frequency of resistance to Cs could be related to the difficulties in testing.  
 
All of the 2079 cases had primary MDR which is indicative of ongoing transmission of MDR-
TB. Factors which allow for ongoing MDR-TB transmission, such as high rates of failure or 
default of MDR-TB treatment, may have created the ideal environment for MDR-TB 
dissemination. Given the high rates of treatment failure in our study, consideration should be 
given to either individualize treatment regimens or increasing the number of medications in 
the standardized regimen. This could be also be due to diagnostic delay or delay in the 
initiation of treatment. Delay in starting appropriate MDR treatment after diagnosis could be 
another factor for advanced disease (56% bilateral disease) observed in this study. The 56% 
of bilateral disease observed in this study is not too different from other findings.(21) 
 
Of note, was the high mortality (18.2%) with almost 60% of them being HIV positive. Our 
findings are consistent with other reports which shows high mortality among HIV coinfected 
MDR-TB patients.(22-24) Efforts to reduce mortality must focus on earlier diagnosis and early 
initiation of second-line TB and antiretroviral therapy. Our study took place before the 
availability of antiretroviral therapy in the public sector in South Africa. 
 
A multivariate analysis of demographic and clinical characteristics with effect on favourable 
outcomes HIV status, new MDR-TB with no previous TB history, resistance to EMB and Cs 
had protective effect against favourable outcomes (OR=1.52, OR=1.10, 0R=1.03, OR=2.22 
respectively) but this was not statistically significant, with the exception of Cs.  
 
Logistic-regression analysis for factors associated with death/failure yielded odds ratios that 
were significant for weight <50kg, resistance to PZA and OFX, which complements other 
studies.(25)  In this study gender was a higher risk 7 more times for death or failure, but this was 
not significant.  
 
Our study has limitations, predominantly those associated with multi-site large scale 
operational research projects conducted under routine programmatic settings. Firstly, we 
attempted to control completeness of CRFs, uniformity across the sites/provinces and 
accuracy of data collection during frequent site visits, calculated culture conversion and 
assigned treatment outcomes ourselves. Secondly, the MDR-TB provincial hospitals had the 
option to send monthly sputum specimens to the SAMRC TB Laboratory in Pretoria for 
culturing and bio-banking, and SLDST when deemed necessary. This however resulted in that 




only for selected patients sputa were submitted to the SAMRC, which limited the applicability 
of any SLD resistance findings across the cohort.  
 
Treatment with first-line drugs before microbiological investigation may have resulted in 
increased drug resistance drug-resistant organisms. Since the treatment options are so limited 
for M/XDR-TB, strains that are resistant to all existing anti-TB medications are likely to emerge. 
Timely identification and referral of patients with the history of treatment failure for culture and 
DST need to be strengthened in order improve patient outcomes and reduce ongoing MDR-TB 
transmission within the community. Thus, as recommended by WHO and South African national 
tuberculosis management guidelines, rapid identification molecular methods and a shorter, 
cheaper treatment regimen for MDR-TB is essential for earlier treatment initiation and better 
outcomes.(26-28) 
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CHAPTER 7  
CONCLUSIONS AND FUTURE WORK 
7.1 CONCLUSIONS AND RECOMMENDATIONS 
 
Drug resistance has compromised the success of treatment of TB and MDR-TB and has 
caused high morbidity and mortality particularly among HIV coinfected patients. This 
necessitated the introduction of rapid drug susceptibility testing (DST) for second-line drugs 
(SLDs) in order to detect, initiate effective anti-TB treatment and prevent ongoing transmission 
of M/XDR-TB. Currently available rapid tests to detect second line drug resistance require 
expensive laboratory biosafety infrastructure that developing countries do not have access to. 
They are expensive and require appropriately trained laboratory staff.  
From a global perspective, many laboratories rely on conventional phenotypic drug 
susceptibility testing which is even more problematic.  The standardization of second line drug 
susceptibility testing (SLDST) is difficult, the technique has a long turnaround time with 3-4 
weeks and some drugs often show discordant results (particularly ethambutol).(1) Until 
recently, phenotypic automated liquid system has been used as the gold standard for 
susceptibility testing of second line drugs.(2) 
The use of Genotype MTBDRsl for rapid detection of second line drug resistance has recently 
been endorsed by a WHO. (3) However only a limited number of mutations can be detected 
with a single test. Thus, in cases where the mutations are outside of the targeted regions, the 
wild-type banding patterns appear, leading to false negative (susceptible) results.(4) 
Pyrosequencing (PSQ) has the potential to overcome such problems.This study therefore 
proposes an algorithm that uses PSQ for DST of XDR-TB.  
This study also describes the prevalence of SLD resistance among MDR-TB patients in the 
DOTS-Plus cohort and its impact on treatment outcomes for these patients in two provinces 
in South Africa; Eastern Cape (EC) and North West (NW) province. Improved knowledge of 
factors that lead to acquisition of second-line drug resistance will help better predict who is 
most at risk of drug resistance and contribute to the development of new tools and strategies 
to combat MDR-TB. In this study treatment success was strongly influenced by the setting 
where the patients were treated. HIV co-infection and being younger was identified as an 
important risk factor for poor outcomes. The shortcomings of the CD4 count not routinely 
recorded by clinicians in both provinces and limiting our description of the cohort in relation to 
severity of HIV infection and treatment outcomes was highlighted. 
 




In this study, the resistance patterns against SLDs among newly diagnosed MDR-TB patients 
in both provinces using Genotype MTBDRsl assay (v 1.0) and how these patients acquired 
resistance during treatment is discussed. The concordance between MTBDRsl and 
sequencing for gyrA and rrs gene was not as high as reported in other studies.(5-6) The 
resistance rate may have been underestimated due to unavailability of phenotypic testing. We 
recommend MTBDRsl v2.0 which is more sensitive than MTBDRsl v1 and is able to detect 
most common mutations involved in resistance to flouroquinolones and 
aminoglycosides/CAP. We also encountered low rates of heteroresistance in association with 
gyrA and embB gene, as reported previously. (7-8) Our findings also show that 45.8% gained 
resistance to SLDs during treatment. Our results are worrying as they suggest that these 
hospitalized patients being treated with a standardized MDR-TB treatment regimen were at 
significant risk of acquiring additional resistance or becoming infected with M. tuberculosis 
strains that had more resistance than their baseline infecting strain. 
 
The high levels of amplification of drug resistance to second-line drugs shown in this study 
generally reflect the implementation of a weak standard regimen and the requirement of 
patients to remain hospitalized for much of the initial treatment. These findings should be taken 
into account when formulating the national policy on treatment regimens for MDR-TB. In view 
of high SLD resistance, we recommend rapid identification molecular methods and a shorter, 
cheaper treatment regimen for MDR-TB and implementation of community based treatment 
for MDR-TB as is currently recommended by WHO and national guidelines.(9-10) 
 
7.2  FUTURE WORK 
 
This thesis has contributed to our understanding of drug resistance in TB, and implications of 
implementing standardized MDR-TB treatment in South Africa. The baseline information of 
the drug resistant strains of TB that are circulating in the country is required in order to better 
understand TB disease. The epidemiological database of drug-resistant TB allows for ongoing 
studies comparing drug resistance patterns across the entire country and the region. Such 
increased knowledge would help in monitoring trends in the prevalence of drug resistance and 
treatment outcomes which are essential for TB control over time. 
 
Our analysis of time from diagnosis to treatment initiation showed that patients had started 
treatment after >180 days did not show a poor outcome compared to patients who received 
timely treatment especially in the EC. This potentially reflects a survival cohort effect in that 
those who survived that long had a better chance of survival. Further research should evaluate 




clinical characteristics of patients who were started on MDR-TB treatment start immediately 
after diagnosis in these two provinces.  
 
The importance of reinfection in nosocomial transmission has previously been described by 
Andrews et al.(11) In our study spoligotyping could have underestimated the proportion of 
reinfection. Secondary genotyping methods with better discriminatory power such as the 
IS6110-restriction fragment length polymorphism (IS6110-RFLP) and mycobacterial 
interspersed repetitive units-variable number of DNA tandem repeats (MIRU VNTR) will give 
better estimation of the proportion of reinfection. 
These finding also have important implications for infection control, because undiagnosed 
highly resistant strains could have been transmitted to contacts during treatment. Further 
research must be conducted to find the most efficient infection control measures to reduce 
transmission of MDR-TB. 
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